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ABSTRACT 
Spectrophotometric studies have been carried out to 
determine the pH dependence of binding of SKF 525 A, 
Brietal sodium and carbon monoxide to cytochrome P-450. 
The optimal pH for metabolic conversion of SKF 525 A has 
been investigated and this agent and its major metabolite, 
SKF 8742 A, have been metabolised in vitro by swine and 
rat hepatic microsomes. 
A suitable gas liquid chromatography assay has been 
developed and used to analyse metabolic production. 
The effects of carbon monoxide, dithiothreitol: 
n-octylamine and of induction of cytochrome P-450 by 
phenobarbital on metabolism of SKF 525 A and SKF 8742 A 
have been investigated. 
Attempts have been made to synthesise SKF 525 AN-oxide. 
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LIST OF ABBREVIATIONS USED 
2-Diethylaminoethyl 2,2-diphenylvalerate 
Nicotinamide adenine dinucleotide phosphate 
Electron paramagnetic resonance 
Gas liquid chromatography 
Thin layer chromatography 
Intra-peritoneal 
Ribonucleic acid 
DeoxYribonucleic acid 
2,4-dichloro-6-phenylethoxyethylamine 
Bovine Serum Albumin 
Instant thin layer chromatography. 
Approximately. 
INTRODUCTION 
SKF 525 A is widely used experimentally as an inhibitor of cytochrome P-450 
but, despite investigation, the mechanism of its action has not been fully 
elucidated. This agent is thought to act as an alternate substrate for 
cytochrome P-450, a situation that would explain its competitive kinetics 
of inhibition . However, the metabolism of some compounds known to be 
oxidized by cytochrome P-450 is not affected by SKF 525 A. Furthermore, 
if this agent is extracted intp benzene and recrystall ized, then the kinetics 
of inhibition changes, despite there being no detectable changes in the 
molecule. 
Use of this agent in live animals causes fat invasion of the liver and 
, 
it is thought that this toxic effect may be due to a metabolite. 
Anders and co-workers have shown that SKF 525 A is metabolised by rat 
hepatic microsomes to SKF 8742 A and an unidentified minor metabolite. 
They were unable to demonstrate metabolism of SKF 8742 A. The same 
workers investigated the kinetics of SKF 525 A metabolism by normal and 
phenobarbital induced, rat hepatic microsomes and found that induction 
greatly increases the rate of de-ethylation of SKF 525 A. They did not, 
however, evaluate their results by gas liquid chromatography to check for 
differences in metabolite patterns formed from induced and non-lnduced 
systems. 
Zeigler et~. have shown that amine oxidase, found in hepatic microsomes, 
is capable of catalysing the formation of N~oxides from tertiary amines. 
Although SKF 525 A is metabolically and functionally associated witb 
cytochrome P-450, the fact that it is a tertiary amine means that it may 
act as a substrate for amine oxidase. However, recent evidence indicates 
• 
that cytochrome P-450 also participates in the N-oxidation of tertiary 
amines. 
Thus, because of the possible therapeutic applications of SKF 525 A and 
its wide experimental use, the objective of these studies was to further 
investigate the metabolism of SKF 525 A and to elucidate the enzyme 
pathways involved. 
CHAPTER 1 
LITERATURE REVIEW 
SKF 525 A (2-diethylaminoethyl 2, 2-diphenylvalerate·HC1) has proved to 
o 
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be of little use as a parasympatholytic agent - its intended purpose - but 
prolongs the sleeping time caused by hexobarbital in rats. However, Cook 
et al. l showed that it had no sedative properties when administered on its 
own,and further work2,3 indicated that SKF 525 A prolongs the duration of 
action of amphetamine, chloral hydrate, barbiturates and some analgesics. 
Brodie et al. 4 showed that the prolonging action of this agent is due to 
inhibition of drug metabolism . In several animal species, the half life 
times of barbiturates, meperidine,ephedrine and aminopyrine were yncreased 
after the administration of SKF 525 A5 . In vitro studies in which liver 
microsomes were used showed that SKF 525 A inhibits the side chain oxidation 
of hexobarbital, pentobarbital and secobarbital; the N-dealkylation of 
aminopyrine, ephedrine, meperidine and dibenaJ:line; the O-demethylation of 
codeine; and the deamination of amphetamine6,7,8. In spite of its general 
inhibitory nature, SKF 525 A does not inhibit hepatic microsomal metabolism 
of a 11 drugs. It does not affect the duration of action of thiopental in 
rats or mice or the activity of thioethamyl in mice2. Similarly, it has 
slight effect on the N-dealkylation of N-methylaniline and several other 
N-substituted anilines, monoethyl-and monobutyl-4- aminoantipyrine, and 
quinacrine by rabbit hepatic microsomes8; the N-demethylation of 3-methyl-4- . 
methylaminoazobenzene by mice hepatic microsomes lO ; the O-dealkylation of 
phenacetin by rabbit hepatic microsomes ll the hydroxylation of acetanilid 
b bb . t h . t " 7 , 12 y ra 1 epa lC mlcrosomes ; 
. . h t" 13 gUlnea plg epa lC mlc rosomes ; 
the sulphoxidation of chloropromazine by 
the reduction of chloramphenicol, p-nitro-
benzoi c acid and other aromatic nitro compounds by rabbit hepatic microsomes 
and the reduction of aminoazo dyes15 (species not given) . It is important 
to mention the species as inhibition of drug metabolism by SKF 525 A may occur 
in a given species but not another,e.g. SKF 525 A inhibits the O-deal kylation 
of phenacetin by rat hepatic microsomes 16 but not by rabbit hepatic microsomes ll . 
The effects of SKF 525 A also vary when the microsomal enzymes are induced, 
as is normally done with phenobarbital or 3-methylcholanthrene,e.g. SKF 525 A 
has little effect on the metabolism of 3-methyl-4-methylaminoazobenzene in 
rats that have been induced with 3-methylcholanthrene but it inhibits the 
N-demethylation of the dye from non-treated rats 17 . Conversely, pre-treatment 
of rats with phenobarbital causes SKF 525 A to inhibit the N-demethylation of 
N-methylaniline but the drug has no inhibitory effects in non-induced rats 18 . 
Anders and Mannering 267 found that microsomes induced with either phenobarbital 
or SKF 525 A itself increased the rate of N-dealkylation of SKF 525 A. No 
mention about the formation of the minor metabolite, under these circumstances, 
was made. Examining the effects of SKF 525 A on hepatic ultrastructure, 
Rogers and Fouts269 showed that the agent affected both the rough and smooth 
endoplasmic reticulum and,furthermore,that i t was strongly bound to the protein. 
SKF 525 A has been shown to be a widely used experimental tool,and although its 
pharmacological effects are supposedly minimal, use of this agent in vivo and 
in vitro is not without effect. Holmes and Bentz258 have shown that SKF 525 A 
inhibits cholesterol biosynthesis in vitro but it is doubtful whether this 
-'.-0-.:.., 
.finding holds ~ vivo for, while serum cholesterol decreases by 75%, total 
2 
cholesterol content of the liver increases. Dick et al. 259 found that 
SKF 525 A reduces total plasma cholesterol and aortic cholesterol in dogs, 
but chronic ad,.linistration results in fatty infiltration of the liver. This 
was ra r idly reversible upon withdrawal of the agent. 
these findings. 
L 260 h f ' d ena as con lrme 
Goudie et ~.26l have shown that SKF 525 A possesses sedative properties when 
used at doses of 25-50 mg/kg,and they indicate that this will affect the 
evaluation of psychotropic drugs. This finding may explain why Takanaka and 
H0268 suggested that "the inhibition of drug metabol ising enzymes (by SKF 525 A) 
can not entirely account for the potentiation of pentobarbital induced narcosis." 
Magus et ~. 262,263 studied the effect of SKF 525 A on the activation of 
hydrocortisone-induced tryptophan pyrrolase of rat liver. This agent was 
shown to enhance tryptophan pyrrolase activity and pituitary involvement was 
evident. These workers point out that SKF 525 A is not as pharmacologically 
inert as was initially thought. 
Possible Mechanisms of Inhibition by SKF 525 A 
SKF 52S A is a very general inhibitor of the mixed function oxidase system 
and affects oxidative biotransformation, glucuronidation and hydrolysis 27 . 
Thus, Brodie4,19 proposed that this inhibitory effect resulted from an 
interaction between SKF 525 A and the microsomal membrane causing permeability 
changes which hindered access of the drug to the enzyme. Gillette20 questioned 
this postulated mode of action because SKF 525 A blocks the metabolism of 
some lipid-soluble substrates such as nicotine, codeine and hexobarbital but 
has no effect on other lipophilic drugs such as monoethyl-4-aminopyrine, 
methylaniline and acetanilid. 
3 
In lon r concentrations however, SKF 525 A stabil izes red cell membranes 232, 
which indicates that the agent may have a non-specific effect on the 
microsomal membrane as well. 
Netter2l suggested that SKF 525 A uncoup l ed the microsomal electron transport 
chain which produced the resulting inhibition. However,SKF 525 A has no 
effect on NADPH-oxidase, NADPH-cytochrome c reductase, cytochrome oxidase 
and glucose 6-phosphate dehydrogenase6,23l. 
Gillette and Sasame22 observed that aerobic preincubation of liver microsomes 
in vitro with NADPH and SKF 525 A results in irreversible inhibition of 
drug metabolism. It was thought that a metabolite of SKF A may be 
responsible for this inhibition. Anders et al. 25 studied the inhibition of 
ethyl-morphine N-demethylation by SKF 525 A and ten cdgeners. The kinetics 
of inhibition were found to be competitive in all cases which suggests 
that these compounds produce their inhibitory effects by combining with the 
Schenkman et ~.23 proposed that a stable active site of the rl-demethylase. 
oxygenated complex of ferrous cytochrome P-450 forms when SKF 525 A is 
actively metabolised in vivo and ~ vitro. This species has an absorbance 
maximum at 455nm and was thought to be responsible for the observed non-
competitive inhibition of drug metabolism ~ vitro. Chemical oxidation by 
potassium ferricyanide causes the 455nm peak to disappear and addition of 
sodium dithionite (a chemical reductant) does not restore the peak. .This 
was taken to indicate that the peak was not due to CO binding to cytochrome 
24 
- P-450. Jenner and Netter reported that recrystallisation of SKF 525 A from 
benzene, as opposed to other solvents such as water and methanol alters the 
inhibition kinetics from non-competitive to competitive. Despite extensive 
physico-chemical analysis, no structural change of the molecule could be 
detected. These findings further complicate the issue. 
4 
Metabolism of SKF 525 A 
Anders et al. 26 studied the metabolism of SKF 525 A in vitro and in vivo 
using gas-liquid chromatography and thin-laY,er chromatography to separate 
and identi fy produc t s. Metabol i sm produced tvlD products; the major one 
was identified as the secondary amine,SKF 8742 A. The other metabolite was 
not identified. Metabolism of SKF 8742 A in vitro did not produce any products. 
o 
I CH -CH CH -CH -CH -C-C-O-CH -CH -N< 2 3 HCl 
3 2 26 ''A SKF 87:2-A H:t H . 
In the in vivo studies neither SKF 525 A nor SKF 8742 A were recovered from 
--- " 
the urine, bile or faeces of rats that had received these compounds; nor 
were meta trJ 1 i tes found in these materi a 1 s. These fi ndi ngs have been 
misint erpreted to indicate that SKF 525 A is metabolically dideet~y'lated to 
yield the primary amine SKF 26754 A233. 
Cytochrome P-45~ 
Before furthe r consideration of SKF S: S A is possible it is necessary to , 
review the work done on cytochrome P-4S0. 
Chance and WilliamsSl were studying the kinetics of cytochrome bS reduction 
when they noticed that uisproportionately large quantities of NADPH are 
requi red to reduce the enzyme. Thi sled ':hem to p,'opose t ,t "unknown 
intermediate rea ~ti ons occur in the reduc ti on of cytochrome Os by NADH". 
5 
F 1 t . 1958 K1' b 52 . t' . h 1 our ye"rs a er 1n ,lngen erg ,lnves 19atlng t e spectra 
cha ra~teristics of the liver microsomal fraction, found that it reacts with 
carbon monoxide forming an absorption band maximal at 450 nm which is 
unstable to treatment with detergents (cho1ate) and acid pH . In attempt ing 
to further characterise the microsomal pigment I Garfinke153 suggested that 
it contained a me t al ion in view of its comp1exing pro perti es but that it 
was not an iron haemoprotein as there was no phot ochemical effect on the 
CO comp1ex52 . Furthermore, a search failed to reveal a and S peaks in its 
spectrum, characteristic of an iron haemoprotein. Omura and Sat034 ,35,37 
confi rmed Klingenberg's conclusions however that the pigment contained a 
haemoprotein. They described its isolation and partial purification and 
characterised it. Furthermore, they found that the cytochrome , cytochrome 
P-450, may be converted stoichiometrically to cytochrome P-420 by treatment 
with heated snake 
54 by Mason et~. 
venom or deoxycholate in the absence of oxygen . Work done 
showed these reactions to be of a very complex nature. 
Omura and Sat037 also showed that cytochrome P-420 underwent aggregation in 
media more acid than pH 7.5. This is indicated by an increase in turbidity 
of the preparation as the pH is lowered . Schoeman et al. 55 confirmed 
this finding and showed, by the use of electron microscopy, that ' the 
aggregates form long tubules . Unlike the inactive, soluble cytochrome 
P-420, these aggregates combine with drugs to produce spectra characteristic 
of active cytochrome P-450. The absorption spectrum was also found to 
vary with pH and these changes were ascribed to splitti ng of the aggregates 
at more alkaline pHs. Mason 56 presented an hypothesis for the stoichiometry 
of mixed function oxidase reactions and this was confirmed by Cooper et ~. 57 
Oxygen consumption was measured polarographically and oxidation of NADPH 
was measured by fluorimetry. It was found that 1 mole of oxygen and 
1 mole of NADP are consumed per mole of l7-hydroxyprogesterone hydroxylated. 
b 
'J 
Using the microsomal fraction from bovine adrenal cortex Estabrook 'et ' al. 58 
investi g~ ted the oxygen activating enzyme for the C21-bydroxylation of 
l7-hydroxyprogesterone to cortexolone. They found that cytochrome P-450 acts 
as the "terminal oxidase" . Cooper et ~. 59 confirmed this result using 
bovi'l e ad rena 1 cortex mi c]" osomes and f urther, foun d that cytochrome P-450 
fulf i lls the same function i n rat ,liver microsomes. This led them to 
conclude that cytochrome P-450 is the final electron acceptor in the mixed 
function oxidase system of all mammals. 
Induction of Cytochrome P-450 
, 
The first evidence indicating that foreign compounds could stimulate 
microsomal enzyme systems was produced in 1954 by Brown et ~. 139. They 
found that liver microsomes from mice fed different di~ts are 
varied demethylase activities. Cramer et al. 140 showed that 
capabl e of 
pretreatment 
of rats with 3-methylcholanthrene and other polycyclic hydrocarbons stimulate 
/~ ,0 
CH 
3 
3-Methylcholanthrene 
the liver microsomal , enzymes that catalyse the hydroxylation of 2-acetylamino-
fluorene, 3,4-benzpyrene141 and zoxazolamin~42. Administration of polycyclic 
hydrocarbons to rats has little effect on the microsomal enzyme systems that 
catalyse metabolism of the type I substrates, chlorzoxazone, p-methoxyacetanilide, 
h b b . t l ' . d hl . 143 G' t 1 144 h d h exo ar 1 a ,amlnopyrlne an c orpromazlne r l em ~~. s owe tat 
phenobarbital has a prolonged and delayed action as an inducing agent. It 
causes an increase in the concentrations of cytochrome P-450, NADPH-cytochrome 
c ret' :ctase and cytochrome bS. Wh~ t 'e level of haemoproteins reaches a 
steady state induced level then t he j'ate of haeme destruction is elevated 
to balance the increased rate of synthesis. Conney and Gilman164 
demonstrated t hat pu romycin bl DC ks the ability of 3-methylcholanthrene or 
phenobarbital to increase the activity of the hepatic mixed function oxidase 
system. Jick and Shuster16S have shown that inducing agents tend to 
reduce protein break dOl 1. In a similar study using 3-methylcholanthrene, , 
Levin and Kuntzman145 showed that cytochrome P-450 exists in two forms, 
each with a different turn-over rate. Treatment with the inducer leads 
to a three-to four-fold increase in the slow phase component . More recently 
Stonard177 ,178 has studied the inductive effects of hexachlorobenzene and 
concluded that this compound represents a new class of inducers which 
, 
exhibits the properties of both the polycyclic hydrocarbons and phenobarbital. 
Fouts and Rogers146 examined the morphological changes in the liver which 
accompany induction by different agents . They found that phenobarbital 
and chlordane stimulate a wide range of microsomal drug oxidations and also 
caused a marked proliferation of the smooth endoplasmic reticulum. 
Benzpyrene and 3-methylcholanthrene only stimulate a few enzymes and do 
not cause proliferation of the smooth endoplasmic reticulum. Studying 
the chemical and enzymatic composition of microsomal subfractions-from rat 
liver after induction with phenobarbital and 3-methylcholanthrene,Glauman175 
noted that phenobarbital increases levels of protein, RNA, phospholipid and 
cholesterol, in what he termed smooth I microsomes while smooth II microsomes 
remain unchanged. Enzymes associated with the electron transport chain 
are also found to be induced. 3-Methyl cho 1 anthrene has no effect on the 
quantities of protein, RNA, phospholipid or cholesterol in the microsomal 
subfractions nor did it increase levels of NAOPH cytochrome c reductase . 
Sladek and ~lannering17 have shown that administration of phenobarbital to 
rats increases absorption in the "absolute" spectrum at 455nm and 430nm 
[ 
proporti onately, while t reatment wi th 3-methylcholanthrene increas ,s the 
absorpti on at 455nm preferentiall y . Thi s led them to suggest that 3-
methyl cholanth rene pretreatment causes .the formation of a new haemoprotein . 
Conney et ~.177 , 1 8 0 investigated the hydroxylation of testosterone at the 
6S, 7a and l6a positi ons . They found that the ratios of CO : 02 required 
for 50% inhibition of each reaction differ s s igni f i can tly . This indicates 
the existence of mo re than one form of cyt ochrome P-450. Imai and Mason168 
studied the binding of ethyl isocyanide to cytochrome P-450which was 
obtained from phenobarbi t al induced animals . They concluded that liver 
. cytochrome P-450 was a s i ngle molecule capable of existing in more than one 
form. Fur ther studies83 supported the vi ew of Conney et ~.180 It was 
shown that SKF 525 A inhibits the N-demethylation of 3-methyl-4-methyl-
aminoazobenzene (3-M~~B) in microsomes from untreated or phenobarbital 
pretreated rats but not in 3-methylcholanthrene pretreated rats. Thioacetamide 
blocks phenobarbital induction but has no effect on 3-methylcholanthrene 
induction. It appears that the new haemoprotein formed - termed cytochrome 
P~450 or P-448 - differs f rom cytochrome P-450 in that it only possesses the 
~ , 
type II binding site68 . The absorption maximum of cytochrome P1450 appears 
at slightly lower wavelength and the absolute spectrum of the two haemoproteins 
differ6l . Parli and Mannering149 studied the relat i ve abilities of 
po lycycl i c hydrocarbons to increase 1 eve 1 s of 3-M~~B N-demethyl ase and 
cytochrome Pf450. They found that each of the agents is only capable of 
producing a certain inductive effect regardless of the size of the dose 
used. Arcos and co-workers142 pointed out that many polycyclic hydrocarbons 
which are potent carcinogens are poor inducing agents and vice versa. 
Schenkman et ~.9l proposed that cytochrome ~-450 was f ormed when 
3-methylcholanthrene or one of its metabolites combined irrevers ib ly with 
the type I binding site of cytochrome P-450. ConverselY,Gnosspelius et ~. 15l 
postulated that cytochrome ~-450 is formed independently of cytochrome P-450 
and does not contain 3-methylcholanthrene or any of its metabolites. 
Bidleman and Mannering150 supported the latter concept and showed that 
cytochromes P-450 and ~-450 are f ormed simultaneously in rats treat ed with 
phenobarbital and 3-methylcholanthrene. Further work on the differences 
in cytochromes P-450 and Pi -450 was done by Fujita et ~. 167. The spectral 
characteristics of these two haemoproteins exhibit small qual itative and 
quanti ta t i ve di fferences. I~hereas cytochrome P-450 gives rise to both 
type I and type II spectra, cytochrome Pi -450 only gives rise to type II 
spectra. Using tritia t ed 3-methylcholanthrene,they showed that cytochrome 
Pi -450 is not complexed with 3-methylcholanthrene or any of its metabolites . 
RecentlY,Fischer and Spencer234 using female rats, have presented evidence 
for a direct effect of polycyclic hydrocarbons on t he formation of cytochrome 
Pi -45( Pretreatment of female rats with benzanthracene causes an increase 
in cytochrome Pi -450. In mature, but not immature, animals actinomycin D 
and puromycin prevent this increase. The results suggest that binding of 
benzanthracene to cytochrome P-450 depends on the level of the sex hormones . 
Thus,young female rats have low estrogen levels and benzanthracene may bind 
to exi sti ng cytochrome P-450 converti ng it to cytochrome Pi -450. Sex 
hormones stabilize cytochrome P-450 and,thus,this change cannot take place 
in older animals: therefore,conversion occurs during or soon after synthesis 
of cytochrome P-450. Alvares and Mannering152 investigated the -mixed-
function-oxidase system of hepatic microsomes and found that in preparations 
from untreated rats different N-demethylase systems metabolise ethylmorphine 
and morphine. In microsomes from rats pretreated with phenobarbital, the 
same enzyme system is involved for the oxidation of both drugs. In a 
recent study, Mailman et ~. 186 have shown that subfractionation of hepatic 
microsomes from untreated rats yields cytochromes P-450 that are qualitatively 
different from each other. In spite of the low concentrations of cytochrome 
P-450 found in uninduced livers,Stanton and Khan188 have developed a high 
yield procedure suitable for the subfractionation. 
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Nebert and Gelboin 153 studied the induction of lryl hydrocarbon hydroxylase 
in cell cultures and found that it appears to require two phases. Firstly, 
synthesis of an induction specific RNA which is translation independent, 
i.e. does not require formation of protein from RNA and,secondly, 
translation related to an induc :bl e specific RNA which is transcription 
independent,i.e. does not require t he formation of RNA f rom DNA. They 
proposed that the increased enzyme activity may be due to an increase in 
the amount of either en yme protein or other protein involved in enzyme 
activation. Nebert154 also showed that the appearance of cytochrome 
P.-450 is dependent upon protein synthesis rather than the presence of , . 
intracellular hydrocarbon as such. Studying the fate of inducers in cell 
cultures Nebert and Bausserman155 found that these agents diffuse passively , 
into the cells and less than 1% of the total agent that enters is 
enzymatically bound to cellular macromolecules. This process may be 
inhibited by SKF 525 A. Half of the physically bound hydrocarbon is 
located on the nuclear or microsomal fractions. It was shown that the 
level of intracellular hydrocarbon decreases after 30 minutes of exposure 
of the cells to benz(a)anthracene. This decrease was thought to be due to 
induction of the microsomal oxygenase . Gielen and Nebert157 showed that 
phenobarbital, DDT and polycyclic hydrocarbons all induce aryl hyarocarbon 
hydroxylase (aryl hydrocarbon hydroxylase is a microsomal mixed function 
oxygenase (cytochrome P;-450) which is induced by polycyclic hydrocarbons) . 
An additive effect is obtained when either phenobarbital or DDT is present 
with a polycyclic hydrocarbon in the medium but not when the hepatocytes 
are treated with phenobarbital plus DDT or with the combination of 
benz(a)anthracene plus 3-methylcholanthrene. The induction of aryl 
hydrocarbon hydroxylase activity by either phenobarbital or benz(a)anthracene 
was shown by Nebert and Gielen158 ,163 to require RNA and protein synthesis 
initially and protein synthesis continuously. They proposed that the action 
of either inducer is at the level of transcription and that with either agent 
there is also a secondary effect at the post-translational level, in which 
the normal rate o'f decay of t he i ndu ~ ed enzyme 
similar work has been done by Hook et ~. 1 76 
is del ayed. More recently, 
Usi ng s-naphthoflavone and 
phenobarbita 1 to i nduc,_, cytochromes Pi -450 and P-450 respectively, Haughen 
et ~.184 concluded that this phenomenon is largely the result of an 
increased rate of de novo protein synthesis rather than a conversion of 
pre-existing polypeptides or a decreased rate of degradation. In other 
studies17 ,159,160,161,162,the genetic differences in the expression of aryl 
hydrocarbon hydroxylase have been described. 
Pelkonen and Karki 166 examined the physicochemical and pharmacokinetic 
properties of barbiturates on the induction of the hepatic mono-oxygenase 
system. They .concluded that the ability of a compound to cause induction 
is rel ated to its lip id solubility, pha rmacokinetic properties and chemical 
groups present in the molecule. 
Lu et ~.169 prepared cytochromes Pi -450 and P-450 from animals pretreated 
with 3-methylcholanthrene and phenobarbital r espectively. Cytochrome 
Pi -450 was much more active in catalysing the hydroxylation of 3,4-benzpyrene 
and cytochrome P-450 was much more active in the demethylation of benzphetamine . 
The reductase fractions from the 3-methylcholanthrene induced liver and the 
phenobarbital induced liver were equally active in the hydroxylation of 
3,4-benzpyrene . After studying the effect of piperonyl butoxide on the 
formation of cytochrome P-450 difference spectra, Philpot and Hodgson170 
concluded that the synergist binds to one form of cytochrome P-450 at a single 
site. They further proposed that an additional form of cytochrome is present 
in hepatic microsomes obtained from non-induced 
substrates or interact with piperonyl butoxide . 
mice which does not bind type I 
193 Wagstaff and Short have 
shown that piperonyl butoxide and some analogues are capable of inducing 
cytochrome P-450. This finding has been confirmed ,by Yu and Terriere19~ 
12 
who showed that the stimula tory effect coul d be blocked by actinomycin D or 
cycloheximide. 
Schoeman et al. 17l examined the differences be tween cytochromes P. -420 and 
-- 1 
P-420. The electrophoretic and spectral characteristics of these two 
preparati ons differed and t his support s tht concept that these two cytochromes 
are separate entities. Three spectrally distinguis ha bl e forms of cytochrome 
P-450 were found in rat liver microsomes by Comai and Gaylor172. The 
relative amounts of the three forms are altered by pretreatment of rats . 
Form III is increased by pretreatment with 3-methylcholanthrene, phenobarbital 
preferentially induces form II and dietary ethanol preferentia lly induces 
form 1. The authors did not imply any structural difference between these 
three forms . 
. RecentlY,Guenther and Mannering173 found t hat the foetal liver is refractory 
to induction by phenobarbital but not to induct ion by 3-methylcholanthrene. 
After parturition, induction of neonatal cytochrome P-450 is possi ble and 
the authors suggested that a control mechanism exists in the foetal rat which 
suppresses induction of cytochrome P-450 but allows induction of cyt ochrome 
Simultaneous administration of 3-methylcholanthrene an6 SKF 525 A 
partially reversed the supression of phenobarbital induction. Working on 
induction in pregnant rats,they showed that cytochrome P-450 is indu.ced 4-fold 
in non-pregnant rats but only 2-fold in pregnant rats . Thi s impairment of 
phenobarbital induction lasted from 3 days before conception to five days 
after parturition . The abil i ty to induce cytochrome Pi-450 was not 
impaired during pregnancy. Again,co-administ ration of 3-methylcholanthrene 
partially reversed phenobarbital induction. The similarities in the response 
between the foetus and the mother led the authors to propose the existence of a 
common regulatory mechanism. 
Imai and Sato196 were :he first workers to produce a cytochrome P-450 
preparation that is homogenous on examination by gel el ectrophoresis . Their 
-preparation of the oxidi sed form is stable in 20% glycerol and, if stored 
at -70oC, loses no activity within 30 days. The reduced form undergoes slow 
conversion to cytochrome P-420 even in the presence of glycerol. Van der 
Hoeven et ~.70 partially purified cytochrome P-450 and NADPH cytochrome P-450 
reductase from rabbit 1 i ver mi c'osomes and inv ~ sti ga ted thei r properti es . 
Further work7l led to the purification and characterisation of four 
distinct forms of cytochrome- P-450. Using immunologic techniques, Welton 
et ~. 148 prepared an antibody to the haemoprotein induced by phenobarbital. 
They showed that the antibody binds preferentially to liver microsomes 
isolated from phenobarbital pretreated rats and they proposed that there 
are radical structural and catalytic differences among the differe t P-450 
haemoproteins. Levin et ~J2 partially purified cytochromes P-450 and 
Pi -450 from animals induced with phenobarbital and 3-methylcholanthrene 
respectively. (As the ratio of cytochrome P-450 to cytochrome b5 is greater 
than 200 : 1 in the active reconstituted system, cytochrome b5 is not thought 
to be an obligatory component of the mixed function oxi dase.) Comparing the 
activities of rat and rabbit cytochromes Pi-450 in the hydroxylation of 
benzo(a)pyrene,Kwalek and Lu182 concluded that these two haemoproteins are 
catalytically different from one another. Further work by Kwalek et ~.73 
strengthened this opinion. They purified cytochrome P-450 from rabbits 
induced with 3-methylcholanthrene and allowed it to react with rat antibody 
produced against cytochrome Pi -450. The poor resultant reaction and the 
enzymatic and molecular size differences led them to conclude that these two 
haemoproteins differed from one another. By purifying cytochromes Pi -450 
and P-450, Ryan et ~~95 showed that these cytochromes have molecular 
weights of 48 000 and 53 000 respectively. Thomas et ~183 prepared an 
antibody against purified rat cytochrome Pi -450 . This showed immunological 
differences between purified rat cytochromes P-450 and Pi -450 and confirmed 
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the presence of multiple fo r •. ls of cytochrome P-450 in purified extracts 
obtained from phenobarbital pretreated rats. 185 d Huang et~, separate 
and purifi ed four different cytochromes P-450 from 1 iver mi crosomes of 
phenobarb ital treated mice. All thFse fractions di f fer in their spectral 
and catalytic properties . Using a i :constituted liver microsonal 
hydroxyl a' e system Kwalek et al .74 co~firmed spectrally that different 
, --
forms of cytochrome P-450 exist. 
Arinc and Phil pot 190 and Jernstrom ~ ~189 have both worked on the 
isolation and purification of cytochrome P-450 from rabbit and rat lung 
respectively and the latter group have shown that this haemoprotein is , 
spectrally different from its hepatic counterpart. Cytochrome P-450 has 
been partially 
housefl i es 192. 
. f ' d f th ' 1 d' . 188,191 d purl le rom 0 er sources lnc u 10 9 mlce an 
Johnson and Muller-Eberhard197 found ' three forms of 
cytochrome P-450 present in hepatic microsomes after pre-treatment of rats 
with 2,3,7,8-tetrachlorodi-benzo-p-dioxin. Forms a,b and c have 
molecular weights from 48 000, 54 500 and 60 000 respectively and forms 
a and b display spectra typical of low spin ferric haeme. Benz(a)pyrene 
activity is catalysed primarily by the b form and acetanilid hydroxylation 
by the c form. 
Using SOS-polyacrylamide gel electrophoresis,Philpot and Arinc200 have 
demonstrated separation of two forms of liver microsomal cytochrome P-450 
with identi cal mol ecul ar weights. Ingl eman-Sundberg and Gustaffson201 
have used electrofocusing to resolve the P-450 LM2 fraction of liver 
microsomes' into four forms. They propose that this technique may be used 
to resolve different types of cytochrome P-450 with very similar physical 
characteristics. 
A d d M . 187 h h th t SKF 525 A ' d h t " 1 n ers an annerlng ave s own a ln uces epa lC mlcrosoma 
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cytochrome P-450. 
and ethylmorphine. 
This results in enhanced N-dea l kylation of both itself 
This activity however does not null ify the microsomal 
inhibitory activity of SKF 525 A because further doses of the agent inhibit 
the newly synthesised microsomal enzymes as well as those that were originally 
present . Furthermore the major metabol ite of SKF 525 A is al so a potent , . 
inhibitor of the mixed function oxidase system26 . RecentlY,Beun ing and 
Franklin199 have shown that administration of SKF 525 A for several days 
increases the total cytochrome P-450 content up to five fold. 
to be an even more potent inducer than phenobarbital. 
Thus it appears 
It has been well established that induction of animals changes the nature 
of cytochrome P_450l7 ,172,lB3 and thus it is important to investigate the 
metabol ism of SKF 525 A under both sets of conditions. 
Drug Interaction with Cytochrome P-450 
Addition of drugs to adrenal or hepatic microsomal systems results in a 
variety of spectral changes which are dependent on the existing conditions. 
Narasimhulu et ~.60 working with adrenal cortex microsomes noted a 
significant spectral change on addition of l7-hydroxyprogesterone . 
Cooper et~J9 and Oldham et~.80 have both shown that solubilized adrenal 
preparations, produced by sonication, still display the same spectral 
characteri sti cs as found by Naras imhul u et ~60. Further work by Cooper 
et ~.62 showed that both the concentration of the drug and cytochrome P-450 
affects the magnitude of the spectral change. This suggests a direct 
binding between the active site of the enzyme and the substrate. Remmer 
et ~.63 noted that hexobarbital and SKF 525 A give rise to the type I spectral 
change while aniline and 2,4-dichloro-6-phenyl-phenoxyethylamine HCl (DPEAl 
addition to liver microsomes results in a type II spectral change. Thi sis 
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characterised by a trough at 390nm and an absorption band at ~ 430nm. 
Two hypotheses were formulated to explain these phenomena: 1) addition 
of substrate resulted in the conversion of an "activated oxygen form" of 
cytochrome P-450 to its oxidized state II) the different type of 
substrates either binds to the haeme of cytochrome P-450 "r resul ts in 
different conformati onal changes. It was thought that the two types of 
spectral changes re sulted from substrate interc.ction on different sides 
of the haeme in cytochrome P-450. Schenkman ~~.64 confirmed findings 
by Cooper et~.62 that the magnitude of the spectral change is dependent 
on the SU Dstrate and cytochrome P-450 concentrations . Furthermore ,Type II 
substrate binding was shown to displace CO from its complex with reduced 
haemoprotein 
et a 1 ~3 they 
-- , 
iron. In addition to the two hypotheses advanced by Remmer 
proposed the exi ster.ce of two di fferent enzymes of the 
microsomal mixed function oxidase, which accounted for the two types of spectral 
change . As a result of experimental data they questioned the first , . 
hypothesis of Remmer et ~.63 and from confirmatory data obtained by electron 
paramagnetic resonance they supported the second hypothesis of ligand 
modification. Using ferriprotohaeme as a model system,Schenkman and Sat067 
suggested that the spectral changes were due to "the displacement of the 
sixth ligand from a hydrophobic region of the apoenzyme (possibly the active 
site) by the substrate". They considered that cytochrome P-450 may exist 
in two forms i) _free enzyme and ii) substrate bound enzyme. Ouri ng 
substrate metabolism the first form is converted to the second,accompanied 
by the type I spectral change. Hildebrandt et ~.6l studied the absolute 
spectra of cytochromes P-450 which were induced by pretreatment of the animals 
with phenobarbital or 3-methylcholanthrene. The results indicated that 
cytochrome P-450 existed in two spectrally distinct forms which they termed 
high and low spin. FurtherSl , it was shown that these two forms of the 
enzyme were interconvertible and were capable of interacting with different 
types of substrates to produce different spectra. The presence of more 
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than one molecular species of cytoc; rome P-450" however, has been suggested 
by t he different product Pi, tterns f ormed duri ng mi crosoma 1 oxi dati on of 
substrates , variations in relative rates of metabolism wi th different 
animal species, and the preferential inf luence of ind ucing ,age- :t s for the 
metabol i sm of some substrates but no t others82 ,83,84. The results of work 
done by Le ibman et ~.85 led them to conclude tha t cytochrome P-450 was a 
single enzyme capa bl e of 
of compounds. In 1970, 
i nterac:t i ng 
Schenkman65 
in two different ways wi th the two cl asses 
re-examined the type I and II spectral 
changes and found t he. t the type I spectrum was also present in the type II 
spectral change. It was the former component which was responsible for the 
asymmetric trough seen in the type II difference spectrum. If this spectrum 
was corrected for the type I con.;:>onent, the resulting spectrum was 
symmetrical and much larger. In 3,4-benzpyrene treated rats, the failure 
of type I substrates to give rise to a type I spectral' change was due to 
an inability of type I substrate to interact, rather then the lack of the 
type I binding site. 
Estabrook et ~.89 proposed that type II spectral changes resulted from an 
interaction of the substrate with the sixth ferric ligand of the haeme. 
They suggested that this binding probably does not lead to hydroxylation 
of the substrate. Gorrod and Temple88 confirmed Schenkman's findings of a 
type I component in type II spectral changes and suggested that this 
phenomenon may explain observed metabolism of type II substrates. 
Jefcoate et ~.86 showed that pre-treatment of animals with 3-methylcholanthrene 
increased the content of high spin (type a) cytochrome P-450 in liver microsomes 
while similar treatment using phenobarbital increased both forms of cytochrome 
P-450 but favoured the low spin (b) form. Schenkman65 pointed out that the 
type a form mentioned above is due to the overlapping of the type I and II 
'difference spectra and the type b form is due to the type II spectrum alone. 
IE. 
Gorrod, Disley and TempleS7 studied the microsomal bi r -ling of the t wo 
structurally related compounds quinoline and isoquinoline. These compounds 
gave rise to a type I and type II spectral change respectively. The 
author: concluded that spectral binding phenomena are lOa result of both 
the ster ic and basic features of the nitrogen and may be infl li~nced by the 
lipophil i c nature of the molesule." It is of interest to note that type I 
substrates tend to increase t ,e rate of cytochrome P-450 reduction66 ,90, 
while type II substrates tend to have tbe opposite effect90 . 
A third.type of spectral change ' as noted by Schenkman et ~.64 and was 
called the modified type II spectrum or reverse type I. This is characterised 
by a peak at about 420nm and a trough at about 392nm in the difference spectrum 
and was thought to be due to the displacement of some pre-existing substance, 
which was bound ~ vivo, from the enzyme9l . Wilson· et ~.92 found that at 
low concentrations, agroclavine interaction with liver microsomes produced 
a type I spectral change. As the agroclavine concentration increased, so 
the reverse type I spectrum manifested itself. It was thought that the 
type I binding was responsible for the metabolic conversion of agroclavine 
as the Ks value for the type I spectral change was very similar to the 
~ value. In a recent studY,Misselwitz et~. 96 studied the effect of 
. temperature on substrate binding to cytochrome P-4S0. It was found that 
type I substrates binding was increased by higher temperatures and the 
reverse applied to the type II substrates. They reaffirmed the idea of 
separate binding sites for the two classes of substrates and their results 
indicated that the type I site was lipophilic in nature. 
Electron Paramagnetic Resonance (E.P.R.) Studies 
Before Narasimhul u et ~. 60 had documented the substrate induced spectral 
changes, Hashimoto et ~.93 undertook a study of microsomal electron 
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transport pathways us i ng. el ectron spin resonance spectroscopy. They found 
presen~ a compound, designated Fex, which they considered was probably a haeme 
protein. Reduction of Fex was catalysed vi a enzyme systems involving NADH 
and NADPH and in this reduced state Fex or a component of the system to which 
it transported electrons, was capable of binding CO reversibly. 1·1ason et !!.l.54 
proposed that Fex was the sulphi de of cytochrome P-420 and that cytochrome 
P-450 in its reduced or oxidized state was the phospholipid complex of the 
sulphide of P-t; 20. In the CO complex, CO was thought to displace -s but 
continued to interact both with it and the phospholipid. In the functional 
enzyme, substrate, oxygen and -S were thought to interact at the protohaeme 
group with the -S act ing as a terminus of the electron transport chain which 
supplied the two ele : trons required for metabolism. 
Crammer, Schenkman and Estabrook94 studied the manner , in which substrate 
interaction with cytochrome P-450 affected the E.P . R. spectra. They 
suggested that a correlation may exist between the two types of optical and 
E. P. R. spectra. They went further, on the basis of their E.P.R . data, to 
support the idea that substrates interact in association with the haeme of 
cytochrome P-450 resulting in modification of the haeme iron ligands. 
Hildebrandt et !!.l.Gl concluded from difference absorption spectroscopy that 
different spin states of liver microsomal cytochrome P-450 'exist which 
change state upon substrate interaction. Whysner et !!.l. 95, working with 
steroids and adrenal microsomes, reached the same conclusions. 
Using rats that had been induced with 3-methylcholanthren~ Jefcoate and 
Gaylor97 produced evidence for a second type of cytochrome P-450 and a 
scheme for protein binding to cytochrome P-450 in the two oxidation and spin 
states of iron. Similar studies were carried out by Peisach and Blumberg9~ 
who suggested that cytochrome P-450 could exist in two forms in which the 
haeme iron may be in either the high or low spin state depending upon the 
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nature of the non-porphyrin ligands of the metal . They did not consider 
it necessary to propose the existence of 
protei ns. Further work by Jefcoate and 
two different cytochrome P-4S0 
Gaylor99 in 1970 reinforced their 
opinion that two forms of cytochr ome P-4S0 were thought to exist. They 
showed that ll-deoxycorticosterone and ll-dehydrocorticosterone occupy 
distinct binding sites on cytochrome P-4S0 and concluded from t heir spectral 
data that these molecules may alter the spin state of the forms of cytochrome 
P-4S0 to whi ch they are bo ~ ; nd. As a result of their studies Reichman , 
et ~.100, 101 proposed that the haeme of cytochrome P-4S0 exists in a 
hydrophobic rocket formed by adjacent a'n ino acid residues. Convers i on of 
cytochrome P-4S0 to cytochrome P-420 is thought to result in an increase 
in the distance between the haeme and the protein surroundings. Type I 
binding supposedly results in removal from the haeme of some of the protein 
ligands. This decreases the electron density on the iron, converts it 
from low to high spin and renders cytochrome P-4S0 more succeptible to 
reduction. 
In 1964,it was shown that cytochrome c reductase was responsible for the 
transfer of an electron from NADPH to cytochrome P_4S077. Estabrook 
et ~.7S proposed the necessity of a component to act as a bridge between 
the flavoprotein reductase and cytochrome P-4S0. These workers also 
studied the enzymatic reduction of cytochrome P-4S0 and found that two 
electrons were required for every molecule of substrate metabolised. 
Further investigation by \vaterman and Hason76 showed that only one electron 
is required for reduction of the oxidised form of cytochrome P-4S0. 
Currently the electron transport system is thought to be divided into two , 
branches; an NADPH dependent flavoprotein 264 coupled with cytochrome 
P-4S072 and an NADH dependent fl avoprotei n62 1 inked to cytochrome bS 265 
These four components are thought to be linked to one another by an 
unidentified "factor x"266. Controversy over the electron accepting 
properties of cytochrome P-450 still persists,and recent results indicate 
1 1 . . d f . . d t· 198 that on y one e ectron lS requlre or l t S re uc lon . 
~ vitro activity requires an NADPH-generating system and the presence of 
14g ++ 78,235,236 Initially, nicotinamide was thought to be essential to 
prevent breakdown of NADP by nucleotidases236 ,11, but more recently it has 
been shown to inhibit drug metabolism237 
Spectra 1 Stud i es with SKF 525 A 
As mentioned previously, Schenkman et al. 23 demonstrated the formation of 
the 455nm peak which appears on metabolism of SKF 525 A ~ vitro and this peak 
was ascribed to the formation of an oxygenated complex. Production of this 
455nm peak is not peculiar to SKF 525 A however and the methylene dioxyphenyl 
compounds such as piperonyl butoxide and safrole also give rise to similar 
o~· '?'" /CH -O-(CH )-O-(CH )-O-CH < . I 2 22 22 4 9 
o 0-.. '(CH) -CH . 
22 3 . 
Piperonyl Butoxide 
0J8/CH -CH=CH < I 2 2 
o 0-.. 
peaks when 
. . 29 ln V1VO 
Safrole 
incubated with liver microsomes, NADPH and oxygen in vitro28 and 
This 455nm peak was thought to be due to the formation of an 
"active intermediate", possibly a carbene or a carbanion30 ,33 which then , 
binds to the haeme of cytochrome P-450. The complex was thought to 
inhibit oxygen activation and further metabolism of sUbstrate31. 
Elcombe et ~.32 found that the 455nm peak disappeared after removal of 
reducing conditions but reappeared immediately on readdition of a reducing 
agent . 
Omura and Sat034 ,35 noted that ethyl isocyanide also gave rise to the 455nm 
peak when added to reduced microsomes. Studies carried out on this 
spectrum indicate that both of the two band s in the Soret region (430 and 
455nm) are caused by the binding of ethyl isocyanide to the reduced form 
of cytochrome P_45034 ,35,36,37,38. Imai and Sat039 found that pH exerts a 
profound effect on the relative heights of the 430- and 455nm peaks such that, 
as the pH becomes more alkaline, so the 455nm peak increases in magnitude 
and the 430nm peak decreases . This behaviour suggests an interrelationship 
between the two peaks and Imai et ~.39 proposed that reduced cytochrome 
P-450 is split into 
equilibrium . They 
interconvertible states, which are in a pH-dependent 
further reported40 that dithionite reduced protohaeme 
interacted with ethyl isocyanide to produce three spectrally different 
compounds. The 4l4nm and the 428nm peaks were assigned to the monoisocyanide 
and the normal di-isocyanide compound ("n" form) respectively. The 
third species ("a" form) was anomalous in that it showed a Soret peak at 
455nm and it was thought to correspond to a polymerised state of the 
di-isocyanide compound of protohaeme. Further work by Imai and Sat04l 
indicates that ethyl isocyanide exerts both a stimulatory and inhibitory 
effect on the microsomal hydroxylase system. The competition between .ethyl 
isocyanide and oxygen for the haeme of reduced cytochrome P-450 is 
responsible for the inhibitory effect, whereas the stimulatory effect is 
thought to result from the change of sensitivity of oxidized cytochrome P-450 
caused by its combination with ethyl isocyanide. 
Franklin42 ,43 showed that amphetamines and some sympathomimetic amines 
produced the 455nm peak when they underwent mixed function oxidation. 
Phenobarbital pretreatl,lentof rats drastically increases the rate of peak 
formation as the levels of cytochrome P-450 and the activity of NADPH 
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cytochrome-c-reductase are lncreased . Induction also increases the rate 
of the deamination reaction which tends to suggest that the 455nm complex 
is formed from an intermediate of this reaction. James and Franklin45 
compared 455nm complex formation between rat and rabbit microsomes and 
found that the latter showed a stereo-chemical pre f erence for the l-isomer 
of amphetamine. With SKF 525 A and propoxyphene much lower rates of , 
metabolism were observed with rabbit microsomes, which is not surprising 
as the .major metabolites differ between the two species. Again,induction 
with phenobarbital was shown to increase the rate of deamination and also the 
rate of 455nm complex formation. This finding adds substance to the 
suggestion that oxidative metabolism at or around the nitrogen is implicated 
. 46 in the 455nm complex formation. Buening and Franklin demonstrated that 
compounds structurally related to SKF 525 A (adiphenine, benactyzine, 
propoxyphene, diphenhydramine, desipramine and nortriptylene) are also 
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capable of forming the 455nm complex when they undergo mixed function oxidation. 
o 
I CH CH-CH~-O-C-CH-CH -N< . '3 
3 2 II I \ . 2 C~ 
o CH CH 
I 2 3 
o 
Propoxyphene 
Again phenobarbital pre-treatment enhances 455nm peak formation . It i s 
in t eresting to note that, contrary to findings of Schenkman !!~.23, 
Buening and Franklin were unable to produce the 455nm complex on metabolism 
of SKF 26754 A. Franklin47 reported that metabolism of p-chloroaniline, 
sulfanilamide, 2-methyl-indoline and dapsone produced complexes, which 
absorbed maxi mally at 448, 450, 451 and 1\ 52nm respectively. These 
complexes resemble those produced by SKF 525 A but differ in that they are 
unstable in the presence of sodium dithionite. It is thought that these 
compounds represent a new class which form complexes during microsomal 
oxidative metabolism. 
48 Mansuy et ~. proposed the following reaction scheme to account for the 
455nm complex formed during amphetamine metabolism. The 455nm complex 
R= CH-O" 2 -
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appeared to be formed after reduction of 5 and, as Franklin49 showed 
that the complex is formed after oxidation of 2 , the metabolite bound to 
reduced cytochrome P-4S0 should have the same oxidation level as 3 or 
its tautomer 4 . 
The following diagram shows the possible redox intermediates between 
amphetamine 1 and its corresponding nitro compound S 
CH CH CH CH 
13 13 13 1 3 
R-CH ~ R-CH ~ R-CH ~ R-CH 
1 I 1 I 
1 NH2 ~ NHOH ~ N=O ? N02 l 
CH 
I 3 
R= CH2-\) R-fi 4 NOH 
Jonsson and LindekeSO investigated the metabolism of phenylalkylamines and 
found that, on metabolism, they produced a peak at 455nm. This was 
dependent on one oxygen atom being attached to the nitrogen. This is 
illustrated in the following reaction scheme. 
HH H 
I I I 
R N·~ R I\I·~ R-N·--" - . ~ - ~,--·- . ~ _ .... I -e- I -W I -e-
OH OH O· 
a b c 
H 
I 
R-N+~ ~ R-N: 
II -W II 
o 0 
d e 
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They suggest that c may represent the intermediate ' etween Ai-hydroxyamphetamine 
and the nitroso compound which binds to the iron in cytochrome P-4S0. 
Possible Metabolic Routes for SKF 525 A 
Anders et ~26 studied metabol ism of SKF 525 A showing it to be 
dealkylated to the secondary amine, SKF 8742 A, and an unidentified minor 
metabolite. Much work has been done concerning the metabolic fate af 
nitrogen containing compounds, similar in structure, to a greater or lesser 
degree, to SKF 525 A. The following review facilitates prediction of the 
possible pathways of SKF 525 A metabolism. 
N-oxidation, N-hydroxylation and N-dealkylation 
Due to the complexity and interdependence of these reactions they shall be 
considered together. 
Norris and Benoit 105 showed . that trimethyl amine is converted to its N-oxide 
when injected into the rat. This result was confirmed by Baker and 
Chaykinl03 using pig liver microsomes ~ vitro. There has been considerable 
difference in opinion on the reaction pathways involved. Mueller and 
Millerl09 presented indirect evidence, which indicated that the in vitro 
demethylation of dimethylaminoazobenzene occurred through an N-hydroxymethyl 
intermediate. McMahon and Sullivanl06 also suggested that direct oxidative 
attack occurred on the methyl group of N-methyl tertiary amines to form the 
N-hydroxymethyl derivative. This would readily have decomposed to the 
secondary amine and formaldehyde. Zeigler and Pettitl07 considered that 
the oxidative attack on the nitrogen atom of the tertiary amine gives rise 
to an intermediate N-oxide. This intermediate is then dealkylated by a 
second enzyme system. Cholate treatment of microsomes did not destroy the 
N-oxidizing capacity of the enzyme. This indicates that the N-oxidizing 
ability of microsomesmay reside in a separate system to that required for 
N-dealkylation . Further workl02 strengthened this view and it was shown 
that SKF 525 A and carbon monoxi de i nhi bi t the N-dea 1 kyl ati on of 
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N,N-dimethy1aniline (O.N.A.) but permit N-oxide formation . Axe 1 rod et ~~ 
showed that both these .agents inhibit the N-dea1ky1ation of the parent 
tertiary amine. 
McMahon222 found that tertiary amines are generally N-dealkylated to a greater 
degree than secondary amine~ , this being due to a correlation which exists 
between lipid solubility and rate of N-dealkylation. Approximately 80% 
of a dose of the d i ethyl substituted terti ary ami ne, d i ethyl propi on, 
undergoes de-ethyl a ti on to produce the secondary ami ne. Only 50% of a 
dose of the secondary amine metabolite is converted to the primary amine223 
Anders et a1. 26 have established that the unidentified metabolite of 
SKF 525 A is indeed present in reduced quantities as compared to the 
secondary amine and the situation outlined above may apply. 
Gorrod and Temp1e137 identified N-hydroxymethyl-carbazole as an intermediate 
in the mammal ian metabo 1 ism of N-methy1 carbazo 1 e both 2!!. vitro and 2!!. vi vo. 
In this report,simi1ar intermediates are shown for a number of compounds. 
However, all of these have a carbonyl group adjacent to the nitrogen which 
may stabilize this intermediate. The carbonyl group in SKF 525 A is well 
removed from the nitrogen atom and is thus unlikely to exert a stabilizing 
influence. 
Zeigler and Pettit104 proposed that the lipid soluble tertiary amine could 
penetrate to the dimethy1aniline (O.M.A.) oxidase where it is oxidized to 
the polar N-oxide . Because of its increased polarity, the N-oxide is 
unable to escape from the lipoidal compartment surrounding the enzyme and 
is thus N-dea1kylated to the less polar secondary amine. They showed that 
sonication disrupts the membrane and this allows the N-oxide to leave its 
site of synthesis. Bickel 124 and Jenner202 pointed out that because 
the N-oxide is far more polar than the parent amine extraction techniques 
must be modified accordingly. 
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Both Baker and chaykinl03 and Zeigler and Pettitl04 agreed that the 
enzymes catalysing N-oxidation and N-dealkylation are very similar. 
Dehner et~. 108 showed that SKF 525 A only inhibits the dealkylation of 
the N-oxide intermediate but does not directly affect t he oxidation of the 
tertiary amine to the N-oxide . Using the aliphatic amine N, N-dimethyl-~-
octylamine (D . N.O.A) they found that increased excretion of N-oxide results , 
when SKF 525 A was injected into the test animals. They cor:cl uded that the 
N-oxide may also be an intermediate in the oxidative N-dealkylation of 
aliphatic tertiary amines. Hodgson ~~. lll studied the metabolism of 
N-dimethylcarbamates. It was not possible to identify the products but 
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they were expected to be either the N-oxide or the N-hydroxymethyl derivatives. 
BattersbyllO has proposed that the N-hydroxymethyl .intermediate may arise 
from the tertiary amine N-oxide intermediate. 
r~asters et al. 1l9 showed that microsomal NADPH cytochrome c reductase 
antibody does not inhibit the N-oxidation of N,N-dimethylaniline and other 
tertiaryamines. Moreover,Reiner and Uehleke120 found that an NADPH 
cytochrome c reductase preparation from microsomes does not catalyse any 
N-oxidation or N-hydroxylation reactions. Bickel et al. 114 studied the 
metabolism of imipramine. Their findings indicated that reactions C and D 
are dependent on both haeme catalysis and enzymatic processes. Furthermore, 
they found that reactions A and B were inhibited by heat pre-treatment, N2, 
CO and SKF 525 A. In a later series of experiments Bickel l15 found that , 
CO, SKF 525 A and excess substrate inhibit tertiary amine demethylation 
~N-OXide~ 
Tertiary Amine A t> Secondary Amine 
but not N-oxidation. This observation is in accord with the findings of 
Gigon et ~.116, who concluded that N-oxidation ' is catalysed by an 
alternative microsomal electron transport system, also dependent on NADPH 
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133 " but not cytochrome P-450. Gorrod showed that N-oxidation and N-d~alkylation 
of l~-ethyl-!:!-methylaniline are different metabol ic routes and N-oxidation 
does not involve cytochrome P-450. Bickel l15 demonstrated that tertiary 
amine demethylation and N-oxidation occur in the 9 000 g supernatant f raction 
and in hepatic microsomes plus NADPH. These two reactions did not occur 
in liver homogenate. N-Oxide reduction and N-oxide demethylation occur in 
the latter system but not the former and all four reactions occur 
simultaneously in liv~r homogenate plus an NADPH generating system. It 
was also shown that imipramine N-oxide formation is far more sensitive to a 
decrease in P02 than the corresponding N-demethylation or aromatic 
hydroxylation125 . As a result of the determination ' of reaction constants, 
Bickel l15 did not consider it possible for the N-oxide to act as an 
intermediate in the N-demethyl ation of imipramine. 
Nicotinamide N-oxide reduction has been investigated by Chaykin et ~.130, 
who showed that the enzyme responsible is a metalloflavoprotein dependent 
on NADH and other cofactors. This compound was also reduced bj xanthine 
oxidase from liver or milk with xanthine acting as the electron donor131. 
Uehl eke 118 stud i ed the effects of phenobarbi ta 1, 3-methyl cho T'anthrene and 
DDT pretreatment on rats in evaluating the N-oxidation reaction. In all 
cases,it was found that induction does not stimulate the 'reaction. The 
converse applies to N-hydroxylation. 
involvement of cytochrome P-450 in some 
work 117 confi rmed tha t cytochrome P-450 
Thi s tends to confirm the 1 ack of 
N-oxidation reactions. Further 
participates in the N-hydroxylation 
of primary arylamines but not in the N-oxidation of N-alkylanilines 
and tertiary amines. Pre-incubation of microsomes at 37 0 C in the absence 
of NADPH rapidly destroys enzyme activity for the N-oxidation of secondary 
and ter tiary amines and precautions against this must be ta ken in 
experimental work. 
Working with amphetamines, Beckett!! ~.12l found that SKF 525 A and CO block 
a-carbon oxidation on either s de of the nitrogen while dithiothreitol and 
cysteamine i nhibit N-oxidation. 
Hhile Beckett et ~.12 l claim that dithiothreitol and cysteamine are specific 
inhibitors of the N-oxidase system, ~Iull et~. 204 have recently investigated 
the inhibitory effects of cysteamine and have found that this agent inhibits 
type I activi ty (polycyclic hydrocarbon substrates) in the mixed function 
oxidase system . Evidence indicates that cysteamine interacts with an 
intermediate electron carrier of non-haeme iron or giycoprotein character 
thus inhibiting mixed function oxidase activity. FurthermOre,Gorrod132 
has suggested that two N-oxidase systems exist, one dependent on cytochrome 
P-450 and the other independent. The ability of a substrate to utilize 
these enzymes is dependent upon its pKa. Thus, a basic amine such as 
SKF 525 A should be N-oxidised by a non-cytochrome P-450-dependent system. 
Non-bas i c ni trogen conta i ni ng compounds, e. g. urethane205 and 4-a"cetyl-
aminobiphenY120~ utilize a cytochrome P-450 dependent system while compounds 
of intermediate pKa e.g. dimethylaniline207 may be substrates for both , , 
enzymes and will thus yield the same products but by different pathways. 
Weisburger and co_workers208 ,209 were uncertain whether the N-oxidation of 
some N-acetylarylamines was mediated by cytochrome P-450 or by a non_cytochrome 
P-450-dependent flavoprotein. Investigating the N-hydroxylation of 
2-acetylaminofluorene Thorgeirsson et ~.2l0 showed the involvement of 
NADPH cytochrome c reductase in the reaction. Immunochemical procedures 
were used. 
3, 
There is sti 11 ull certa i nty as to whether the cytochrome P-450-dependent 
N-oxidase system is identical with that involved in other cytochrome P-450-
mediated processes. Evidence from some studies suggest that this is not 
the case. . IIhil e pretreatment of hamsters wi th 3-met hyl cho 1 anthrene 
distinctly increased microsomal acetylaminofluorene 
l · ttl d·ff .. h d 1 t· 211 ,212 was 1 e 1 erence 1 n r1 ng y roxy a 10n 
N-hydroxylation, there 
Similarly, pretreatment 
of rats with 3-methylcholanthrene resulted in an increase in ring 
hydroxylation of acetylami nofluorene but little change in the N-hydroxylation 
pattern213 Zeigler et ~.112 succeeded in purifying a microsomal N-oxidase 
from pork liver microsomes. They deter mi ned that it was an NADPH dependent, 
but cytochrome P-450 independent fl a voprotei n whi ch catalyses tl-oxi dation. 
Use of SKF 525 A as an inhibitor greatly increases N-oxide production while 
use of CO/02 mixtures have less effect
l13
. This could indicate that 
SKF 525 A is either a more effective inhibitor of further oxidation or that 
it was metabolised by the amine oxidase, as it is itself a tertiary amine, 
and contributed to the amine oxide formation. This enzyme appears to 
possess an activator site as well as a catalytic site214 ,215,216 Substrates 
such as primary alkylamines, which are not N-oxidized by this system, can 
interact with the regul atory site and enhance the rate of N-oxidation of 
other amines216 ,241 . The pH optimum for this enzyme has been shown to be 
above pH 8215 . Burke and Mayer239 have shown that phenobarbital pretreatment 
of animals does not induce amine oxidase. 
Beckett and Al Sarraj123 showed that there is considerable variation in 
species dependent metabolism of amphetamines and Gorrod138 has reported that 
hepatic microsomes prepared from rats have very poor N-oxidizing capacity, 
while those prepared from the guinea pig are far more active. Bickel 124 
has pointed out that N-oxides are usually minor metabolites and it is 
possible for them to have a more potent activity than the parent amine. 
Thus, metabolite 1 of Anders et ~.26 may well fit into this catetory and 
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possibly account for the toxicity of SKF 525 A. Exceptions to this rule 
of thumb exist however, and Beckett and Hewick 126 have shown that !,-o;, ide is a 
. major metabolite of chlorpromazine biotransformation in vitro. Demonstrati on 
r(YS~ ~NM, 
I Cl CH 
. CH -CH -CH -N< 3 
2 2 2 CH 
Chlorpromazine 3 
C(S)) I" I" 
,,0 N ~ 'Cl 
I CH 
CH-CH-CH-N< 3 
. 2 2 2 I CH 
Chlorpromazine N-Oxide + 3 
o 
of this fact is dependent on the correct extraction procedure . Beckett and 
EissenlD showed that chlorpromazine is N-d ealkylated and the resulting 
compounds are then N-oxidized to form hydroxylamines. Primary and 
secondary amines may also be N-oxidized to produce hydroxylamines. Tertiary 
amines may be deal kylated ~ vivo and in vitro to produce secondary amines, 
which may be N-oxidized to form hydroxylamines 128• These pathways may be 
pertinent to SKF 525 A metabolism and are known to apply to di methyl-
h t . 128 d h d' t . 129 t b l ' amp e am1ne an p en 1me raZ1ne me a 0 1Sm. 
Beckett and Belanger134 , studying the metabolism of phentermine and 
chlorphentermine, proposed a mechanism whereby a complex of the oxygen 
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radical/flavoprotein with the nitrogen radical cation give rise to both the 
nitroso and hydroxylamine derivatives. Separate mechanisms for the 
formation of each of these compounds are involved. A'l extension of this 
135 . 
work outlined general pathways for the metabolism of primary aliphatic 
amines to yield oximes. hydroxylamines. C -nitroso products. ketones or 
aldehydes and secondary amines to yield primary and secondary hydroxylamines. 
nitrones and the dealkylated and deaminated products. They concluded 
that there is a common metabolic N-oxidative pathway for primary and secondary 
amines which involves different enzymes from those responsible for the 
N-oxidation of tertiary aliphatic amines. Extrapolation of these findings 136 
provided analogous pathways for the metabolism of primary and secondary 
aromatic amines. 
Stereochemical features around the 
metabolic conversion. Hewick and 
nitrogen atom also affect the nature of 
Beckett203 • studying metabolism of 
phenothiazine derivatives with different side chains. found that. generally. a 
dimethyl amine group attached to a straight chain with 2. 3 or 4 methylene 
groups is N-oxidized by rat liver microsomes. However. N-oxidation is 
abolished when a diethylamino is substituted in place of the dimethyl amino 
group and steric factors are thought to be responsible. This is the state 
of affairs existing for SKF 525 A and thus it is unlikely that this agent 
should form the N-oxide. However. as a rule. N-oxidation of tertiary 
1 · h t" . 1 1 1 t " t t" 220 a 1p a 1C am1nes occurs 1n arge mo ecu es con a1nlng wo aroma 1C r1ngs 
and SKF 525 A falls into this catetory . Nevertheless. it is likely that 
steric factors should override this latter consideration. 
Antihistamines are also capable of forming N-oxides221 Using 1 iver 
preparations from guinea pigs. the N-oxide metabolite represented about 15% 
of the incubated amount of orphenadrine. whereas pheniramine. chlorpheniramine 
and brompheniramine produced 15%. 15-30% and 40% N-oxide respectively. 
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01 ~ 'CH 
I 3 CH 
CH-O-CH -CH -N< 3 I 2 2 CH3 
o Orphenadrine 
~ 
o 
I CH CH-CH -CH -N< 3 
I 2 2 CH3 
o R -H 
R -Cl 
R -8r 
Pheniramine 
Chlorpheniramine 
Bromopheniramine 
It is interesting to note that,in spite of the structural similarity of 
the latter three antihistamines mentioned, N-oxide production varies 
considerably. Thus, it appears that long range steric effects exert 
more influence than is apparent at first sight. These factors make it 
more difficult to predict the metabolites of a molecule as complex as 
SKF 525 A. 
Fenfluramine is structurally related to SKF 8742 A. Beckett et al. 2l7 ,2l8 
showed that fenfluramine is metabolically converted to the hydroxylamine (2), 
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the ketoxime (5) and the nitrone (4). 
Metabolic Conversion Of Fenfluramine 
\~ 
O~ -CH-CH-NHC H - 2 1 2 5 
1 CH 
3 
CE V 
\3 OH 0 1 " I - CH -CH-N-C H \"- 1/ 2 1 1 2 5 
\ CF: 
\3 OH 
O 1 \ I -CH -CH-N-C H \\ 1/ 2 1 2 5 
1 CH OH .£ CH 
?~ 3 3 
CE \3 . CH 
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4. H 0 
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Metabolic Conversion Of Ethylamphetamine 
0" -CH -CH-NH - 2 I 2 O~ -CH -CH-OH - 2 I 
2 CH 
3 
1 CH 
3 
0" -CH -C-CH - 2 II 3 0" -CH-CH-NHC H - 2 I . 2 5 
3 0 .i CH 
3 
0" -CH -CH-N=CH-CH - 2 I I . 3 
5 CH 0 
3 -
0" -CH-CH-NHC H - 2 I 2 5 
6 CH 
3 
.. 
It is not definitely known whether the nitrone is an actual metabolite or 
if it is formed by non-enzymic r"eactions. The same workers have 
investigated the me t abolism of metoclopramide ~ vitro and have 
Cl 
\ 0 
H N-O" -g-NH-CH -CH -N<C2HS 
2 - 2 2 CH 
\ " 2 S 
OCH 
3 
Metoclopramide 
shown this molecule to be di-de-ethylated230 The metabolism of 
ethyl amphetamine (6) gave rise tothe following metabolic products219 : 
1. amphetamine, 2. l-phenyl-propan-2-o1, 3. phenyl acetone, 
, , 
4.N-hydroxyethylamphetamine and 5.a-methyl-N- (1 - phenylprop-2 -yl). 
ni trone. (See page 37). 
Deami na t ion 
Hucker and co_worker224 ,225 have studied the metabolism of amphetamine 
using rabbit liver microsomes and claimed that,under their conditions, 
CH
3 ()-CH2-6=NOH 
Phenylacetone 
Oxime 
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phenyl acetone oxi~e was the key intermediate in the oxidative deamination 
of the drug. The results of Parli et ~. 226 , 227 under the same conditions 
differed, and they demonstrated the incorporation of molecular oxygen into 
phenyl acetone whereas the f·athway of Hucker et a 1. 229 .225 woul d i nvo 1 ve 
, --
the incorporation of oxygen from water. The work of Hes and Sternson228 
confirms these findings. Deamination of aliphatic amines substituted 
with large groups may also occur . In the metabolism of propranolo1 229, 
it was found that isopropylamine is present as a metabolite. · Beckett 
et ~.122 have shown that oximes may be involved in the deamination 
pathwa.ll and that N-oxide formation preceeds oxime formation 123 . 
Physiological Factors Affecting Drug Metabolism 
The pharmacological effect of a drug may vary according to a number of 
different physiological factors which are often interrelated. Thus. it 
is important to consider the species, strain, sex, age etc. of the test 
animals used to evaluate drug metabolism. 
Williams270 has reviewed species differences in drug metabolism. Parke27l 
has shown that the ~ vivo hydroxylation of aniline varies according to 
the species used,and Creaven et ~.272 have confirmed these results by 
monitoring the species variation in the in vitro hydroxylation of biphenyl. 
Strain variation within a species also causes differences in drug 
metabolism,and a study of imipramine and aminopyrine N-demethylase, ' 
p-nitroanisole O-demethylase and aniline 4-hydroxylase in three different 
strains of rat indicated differences in metabolism273 . Jori and 
Pescador274 have revealed that strain differences exist in the induction 
of rat microsomal enzymes by 3-methylcholanthrene and phenobarbital. 
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The sex of the .test animal , 1so affects metabolic patterns and one of the 
factors involved is the balance between the male and female sex hormones275 . 
Irradiation of male rats decreases aminopyrine metabolism but it has no 
effect on female rats. This is t hought to be due to the inhibition of 
the synthesis or release of testosterone276. 
Age affect s development of drug metabo1ising enzymes and after birth there , 
is an in i tial rapid increase for 2-4 days and,then,a slower rise in 
activity for about 30 days. This pattern holds for a number of species277 
After reaching a maximum, activity may decrease to a constant lower level, 
e.g. biphenyl-4-hydroxy1ase, it may slovl1y increase, it may remain constant 
or it may decrease to negligible 1eve1s278 . 
Jori et a1. 138 found that diurnal variation also affects drug metabolism 
with maximal activity occurring at night. Variations range from 10-50% 
of average values and reversal of light and dark sequences leads .to 
reversal of metabolic patterns. 
Pregnancy decreases drug metabo1ising activity in the rat and rabbit147 ,279 
while rabbits at full term pregnancy show no reduction in liver weight 
or cytochrome P-450, glucurony1 transferase activity decreases by 20% 
and coumarin 7-hydroxy1ase activity by 60%. These changes are prevented 
by pretreatment of animals with phenobarbita1 279 . 
As the liver is the main site for drug metabolism in the body hepatic ' , 
disease will affect metabolic patterns,e.g. malarial infection causes 
interference of metabo 1 i sm280. 
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CHAPTER 2 
OPTIMISATION OF SKF 525 A NETABOLISM m VITRO 
Objectives 
Buffers with a pH of 7,4 are most commonly used in experiments dealing 
with hepatic microsomes. The rationale behind their use is uncl ear and, 
to the author's knowled ge little investigation in this field has been , 
performed. When dealing with ~ vitro metabolism,the metabolic system 
as a whole should be investigated and not merely the terminal ox i dase. 
Thus, .the properties of other enzymes involved should be taken into 
consideration as their efficient function is essential for optimal 
metabolic conversion. Isocitrate dehydrogenase forms part of the NADPH 
generating system required for reducing equivalents. , The optimal pH for 
activity of this enzyme is 7,8249 and hence its use in a medium at pH 
I I 
7,4 will not be ideal. 
It is, therefore, the objective of these studies to investigate the 
following: 
i. The effect of pH on drug binding to cytochrome P-450. Schenkman 
et al. 64 have shown that the type 1 difference spectrum results from 
interaction between cytochrome P-450 and the substrate and furthermore the 
magnitude of the type 1 spectrum has been shown to parallel enzyme 
t · 't 253 ac 1 Vl Y It is on the basis of this rationale that the effect of pH 
on the magnitude of the type 1 spectral change will be investigated . 
ii . Procedures required for metabolism of SKF 525 A and SKF 8742 A, 
iii . . The effect of pH on metabolism of SKF 525 A and SKF 8742 A. 
iv . The stability of the metabolites. 
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i) Material s and Methods 
a) Preparation of Microsomes 
Microsomes were prepared according t o the method of Cinti et ~.244. 
The sex of a rat was noted, it was then kill ed by cervical dislocation and 
weighed. 
weighed . 
The liver was removed, immersed in ice cold 0,9% NaCl and 
All subsequent operations were performed at 0:. 4oC. The 1 iver 
was perfused with 0,9% NaC] to remove haemogl obi n and ensure a rapi d fall 
in tissue temperature. It was then sliced up and a 10% mi xture was 
prepared with 0,25 M sucrose . Thi s' was homogeni sed with 6-8 excurs ions 
of the Thomas tissue grinder, and the resulting mixture was centrifuged at 
600g and 12 OOOg for 5 and 10 minutes respectively in a refrigerated M.S.E.1B 
high speed centrifuge. This removed the cell debris, nuclei and 
mitochond ri a. The supernatant was treated with 8~1 Ca++ and centrifuged 
at 27 OOOg for 15 min which allowed complete sedimentation of the microsomes 
into a compact pellet. The pellet was washed (to remove any remaining 
haemoglobin) by resuspension in an equal volume of 1, 15% KCl and divided 
equally between six centrifuge tubes. These were spun for a further 
15 minutes at 27 OOOg, the clear supernatant was discarded and the microsomal 
pellet immersed in buffers of varying pHs. The pellets were stored on 
ice and homogenised as required. All animals used in these studies were 
male, 300-350g, Rhodes University Tick Research rats and they were 
sacrificed at 09hOO for each experiment. 
All glassware used was soaked in chromic acid, well rinsed with distilled 
water and dried in an oven. 
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b) Protein Determination 
Two methods were used. 
i) Goa's Modified Microbiuret Protein Determination 
~lethod . O,2ml protein solution was added to 3,8ml 3% NaOH followed 
by O,2ml Benedict's reagent. After 15 min the absorbance was read at 
550nm in a lcm path length cell. 
Benedicts Reagent. 17,3g trisodium citrate and 109 sodium carbonate were 
dissolved in about 80ml of hot water. This was filtered into a graduated 
vessel and made up to 85ml with water. l,73g of copper sulphate .was 
dissolved in about 10ml water and this was added to the citrate-carbonate 
solution with constant stirring and made up to 100ml with water. 
Calibration curve: Bovine serum albumin (B 5 A ) of known water content 
was dissolved in 0,9% saline to a standard concentration (octanol was used 
to prevent foami ng) and diluted \oJith sal i ne to produce protei n concentrati ons 
in the range desired. A calibration graph was constructed. 
Blank: The alkaline Benedict's solution was prepared as above but O,2ml 
saline was used instead of the protein solution. Determinations were 
performed in duplicate. (Using this method, the Beer-Lambert Law should 
be obeyed up to 10 mg/ml of protein.) 
ii) Miller's Nodified Lowry Protein Determination247 
The coloured complex formed in this assay is only proportional to the 
protein concentration in the range of 50 to 200 ~g/ml. Thus the 
microsomal suspension had to be diluted accordingly. 
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11ethod . B S A of known water content was used as .the standard protein 
and a calibration curve was constructed using standard solutions of protein 
in place of the protein test solution. All determinations were performed 
in dup1 icate. One m1 of the protein solution (or 1m1 water for the blank) 
was added to 1m1 of the copper reagent, mixed and allowed to stand for 
10 min at room temperature. Three m1 of diluted Fo1in-Pheno1 reagent was 
added and immediately mixed well. The tubes were heated for 10 min at 
50 °c in a water bath and the optical density was read at 540nm. The 
. values obtained from the calibration curve were corrected for the dilution 
factor. All reagents were freshly prepared from stock solutions . 
Fo1in-Pheno1 reagent: Dilute 5 m1 of Fo1in Phenol Reagent with 50m1 of 
distilled water. 
Copper reagent: (from the following stock solutions) 1m1 1% copper 
sulphate; 1m1 2% sodium tartrate; 20ml 10% sodium carbonate in 0,5 M 
NaOH. The precision of these two methods was tested and compared using 
the same protein solution. 
used to measure absorbance. 
Results 
See Fi gure 1. 
Discussion 
A Beckman D.B.25 UV spectrophotometer was 
Miller's modified Lowry protein assay was found to be far more accurate 
than the biuret method and was used in preference . These results concur 
with the findings of A1bro283 who investigated various methods for 
microsomal protein determination. 
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Buffers 
Two types of buffers are normally used for microsome preparations, viz. 
phosphate and Tris. Neither of these are ideal, for, above pH 7,5, 
phosphate has poor buffering capacity and below pH 7,5, the same applies 
Ideally the buffer used should approach the ionic strength , 
and composition of the hepatic intracellular fluid. Attempts were made 
to produce such a buffer but they were not successful and thus it was 
decided to use the conventional buffers. S0rensen's phosphate buffer248 
was used for these studies. 
A Beckman Acta M Vl ultraviolet spectrophotometer was set up as detailed 
by the operating booklet. 
Wavelength scanned:500-360nm (Tungsten source) 
Period selector switch: 2 
Span control: 0,02 
Mode switch set at DB Servo slit position. 
Slit program selector set in program position. 
3ml of the microsomal suspension were pipetted into each cuvette and 
placed in the sample compartment of the spectrophotometer. Absorbance 
was scanned between 500 and 360nm and the instrument was adjusted to 
obtain a straight baseline. It was found that dilute microsomal 
suspensions (a.lmg/ml) gave a more satisfactory baseline . 
The type I difference spectrum was observed by performing a titration 
with both SKF 525 A and Brietal sodium. These drugs were added in 
increasing titres using a Hamilton syringe. l4here large vol ume additions 
were involved an equal volume of distilled water was added to the reference 
cuvette. The type I difference spectrum was run four times for each 
addition of drug and the average of these four readings was used. 
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As this was a lengthy procedure, experiments were repeated starting from 
either end of the pH range to ensure that enzyme degradation did not 
affect the results. The final results were obtained by using 'a single 
addition of 10 ~l each of 4 x 10-4 M SKF 525 A and Brietal sodium. 
Results were evaluated by measuring the difference in height between the 
four peaks at c.390nm and the four troughs at 420nm. These values were 
averaged, corrected for baseline anomalies, protein concentration and 
finally expressed as a percentage of the maximal difference obtained at 
each pH. Carbon monoxide binding was studied in a similar fashion. 
After a suitable baseline had been obtained, the microsomes were pooled and 
the iron in cytochrome P-450 reduced with c.5mg sodium dithionite. Three 
ml of the suspension was pipetted back into the reference cuvette and the 
remainder was gassed with carbon monoxide for 1 min. ' This suspension was 
protected from light to prevent the CO-cytochrome P-450 complex dissociating. 
The spectrum was run and results were evaluated as described above . 
Male, 350-400g rats were used in this study. 
Results 
See Figures 2-4. The different lines on the graphs refer to duplicate 
experiments. 
Discussion 
It appears that the optimal ,pH for formation of the type I difference 
spectrum and hence binding of the drug to cytochrome P-450 is c. pH 7,8. 
Binding of carbon monoxide to reduced cytochrome P-450 appears to have a 
slightly lower optimum at c. pH 7,7. The pH optimum for type I binding 
and carbon monoxide binding should not be expected to be the same as 
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different binding sites are involved. As type I binding is a prerequisite 
for SKF 525 A metabolism, it was expected that pH 7,8 should also be 
optimal for me t abolism. 
2. Metabolism of SKF 525 A and SKF 8742 A 
Materials and Methods 
a) Preparation of microsomes. The microsomes were prepared as described 
earl ier. 
b) Buffer Tris- HCl 
A Tris-HCl buffer248 (pH measured at 38 °C)was used in all metabolic 
studies. The pH of the buff er used in the initial studies to establish 
metabolism was 7,8. This figure agreed with the results of the pH 
dependent drug binding experiments. Furthermore the pH optimum of 
'isocitrate dehydrogenase u~ed in the NADPH generating system is 7,8249 . 
c) ' Metabolic incubations 
10011 incubation flasks, complete with rubber stoppers, were used. The 
-following components were added to each flask and the order of additions 
was kept constant to prevent variation. 
1. Mn++/Mg++ solution (5mM MgC1 2 + 0,005mM MnC1 2/O ,2ml) 0,2ml 
249 
2. Distilled water 0,5ml 
3. N A D P 1,4mg 250 
4. Isocitric acid 2,5mg 250 
5. SKF 525 A/SKF 8742 A 1,Omg 26 
6. Microsomal suspension ~.6mg protein/rnl) 1,Oml 
7. Isocitrate dehyd rogenase o 2 ' 249 , mg 
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The final volume of each incubation mixture was 2,Oml. 
The NADPH generating system functioned in the following manner250 : 
Mg++ 
D,L Isocitric acid + NADP • a-Ketog lutaric Acid + NADPH 
Mn++ + 
Isocitrate + H + CO2, 
Dehydrogenase 
A glass marble was added to each incubation flask to facilitate mixing 
and increase the surface area exposed to the atmosphere. Before incubation, 
each flask was gassed with oxygen and 
for 30 min at 38 °c (body temperature 
sealed. Incubation was performed 
of the rat) and the rate of oscillation 
of the metabolic shaker was kept constant at 120 cycles/min. 
To detect metabolism the following controls were us ed: 
1. Complete incubation mixture (Test) 
2. Incubation mixture minus isocitrate dehydrogenase 
3. Incubation mixture minus drug 
4. Incubation mixture minus microsomes. 
It was expected that control No.2 may give rise to some metabolism 
due to the presence of reducing equivalents in the . microsomal suspension. 
Control No.3 would indicate adventitious g.l.c. peaks not due to the drug 
or its metabolites, and control No.4 would unmask non-microsomal 
conversion of the drug. 
Enzymatic processes were stopped using lm1 10% trichloroacetic acid, 
which precipitated the protein. The mixture was filtered and the filtrate 
was brought to pH 9,5 using concentrated ammonia solution (c.12 drops). 
As the physical properties of the minor metabolite were not known, five 
different extraction procedures were investigated to find the most 
efficient process. 
52 
i. Before alkalinising the filtrate, petroleum ether was used to extract 
any lipid that may have been present. This procedure was discontin'ued 
when the ,extractant was found to contain SKF 525 A. 
ii. Before the addition of ammonia, the filtrate was freeze dried in 
ampoules, which were then sealed under nitrogen and stored. ~Jhen 
required, the contents were alkalinised with ammonia vapour and extracted 
with chloroform. This procedure was successful but too slow and 
cumbersome for the large number of samples used. 
iii . The alkalinised filtrate was extracted with 4 x 3ml chloroform, 
which was passed through anhydrous sodium sulphate to remove the water . 
The chloroform was evaporated in a water bath . 
iv. As the minor metabolite was possibly a polar N-oxide, 2 x 3ml 
diethyl ether and 2 x 3ml n-butanol were used sequentially. 
was evaporated at 70 °c under vacuum . 
The extract 
v. SKF 525 A and its metabolites were tested for stability in the 
presence of d;ethyl ether. Metabolic extracts were analysed by"g.l.c . 
and the chromatogram was retained to check against a chromatogram of the 
same metabolic extract which had been incubated with diethyl ether . No 
difference between the two chromatograms was detected and so 3 x 3ml 
aliquots of diethyl ether were used to extract the alkalinised filtrate. 
While the latter three of the methods tested were all practical, the use 
of ether was preferred as it was very easy to evaporate and three 3ml 
aliquots extracted SKF 525 A quantitatively from the filtrate. 
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All evaporated extracts were gassed with nitrogen in a boiling water bath 
to remove any traces of remaining water and, as required, they were made 
up ~/ith a specific volume of analytical grade methanol for injection 
into the g.1. c. 
Results 
(For details on g.l.c. techniques see chapter 3.) 
After elinlinating various sources of metabolite contamination (plastic 
funnels etc.) clean g.l.c. traces were obtained. , As the recorder was 
run at the same chart speed, detection of metabol ites was simpl ified by 
superimposing the test chromatogram over each of the control chromatograms 
in turn. Peaks which appeared on the test chromatogram but nQt on the 
, 
controls were shown to be metabolites. SKF 525 A was shown to form 
SKF 8742 A with a retention time of 8,97 min and a minor metabolite with a 
retention time of 7,31 min. 
SKF 8742 A was shown to form a metabolite with a retention time of 7,29 
min. 
Discussion 
These results on the metabolism of SKF 525 A agree with the findings of 
Anders et al. 26 . However these workers did not detect any metabolite 
of SKF 8742 A. Judging by the almost identical retention times, it 
appears that the metabolite of SKF 8742 A and the minor metabolite of 
SKF 525 A are the same compound. 
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3. pH Dependent Metabolism of ·SKF525 ·A·and ·SKF8742 A 
~laterials and Methods 
These studies were carried out as described with the following adjustments. 
1. After the final washing with 1,15% KCl the microsomal pellets were 
homogenised in Tris-HCl buffers of pH ranging from c. 7,2 - 8,6 . 
2. After the metabolic extracts had been prepared, metabolites which may 
have adhered to the walls of the sample tube were washed down with ether. 
This helped ensure accurate quantitation. To visualize quantitative 
peaks in the g.l.c., a concentrated injection of 10 III Vias required. 
Thus, the volume of methanol used to dissolve the metabolites was 
necessarily small (100 Ill) and hence it was not possible to ensure , , . 
dissolution of metabolites remaining high up the walls of the sample tube. 
3. A Chaney adaptor was used to deliver reproducible injection volumes. 
4. t~ale 300-350g rats were used. 
Results 
Four flasks were used for each pH studied, these results were averaged 
and expressed as a percentage of the maximal percentage conversion of 
SKF 525 A to its metabolites. 
See Figures 5 and 6; The different graphs refer to duplicate experiments. 
Discussion 
It appears that the pH optimum for formation of metabolite 1 from SKF 525 A 
differs somewhat to that for the formation of SKF 8742 A. It is difficult 
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to reach a definite conclusion with results from a study such as this, 
as Gorrod132 has pointed out. A chan r ~ in the pH may affect the 
stabil ity of one of the me t abol ites. Furthermore if different enzyme 
systems are involved in producing the metabolites, then pH changes may 
affect the relative abundance of one or the other . 
It appears from this study that the production of both SKF 8742 A and 
metabolite 1 are mediated by cytochrome P-450. It is difficult to 
reconcile the differences in pH opt i ma for the production of both 
metabolites but were amine oxidase involved, one would expect metabolite 
formation to be enhanced at more al kal ine pHs (c.8 ,6). 
4. Stabil ity of r~etabol ites 
Materials and Methods 
Metabolites were prepared as described and samples were analysed by g.l.c. 
These samples were allowed to stand unsealed under normal room conditions 
for three weeks after which time they were re-analysed by g.l.c. The 
chromatograms were compared. 
Results 
No detectable change took placeduring exposure to air and light. 
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CHAPTER 3 
GAS LIQUID CH ROt1ATOGRAPHY (g.l . c. ) 
Objectives 
Anders et al. 26 in their studies of the metabolism of SKF 525 A nd 
SKF 8742 A were able to resolve two metabolites of SKF 525 A an d to 
identify one of them by g.l.c . on A/W DMCS treated chromosorb w coated with 
2% SE 30 packed i nto 2m 6,5mm/0.D. glass columns. They were, however, 
unable to identify the second metabolite or to detect metabolism of 
SKF 8742 A. 
It is, therefore, the objective of these studies to develop a suitable 
method to detect the metabolites, optimise condition~ to enable the 
columns to be used for g.l.c./mass spectrometry and develop a quantitative 
procedure for analysis of the metabolites. 
~laterial sand t·1ethods 
Throughout these studies a Hewlett Packard 5830 A chromatograph fitted 
with dual flame ionisation detectors (F.LD.) was used. The following 
gas pressures were kept constant during operation. High purity nitrogen 
carrier gas 60 p.s.i., F.LD. hydrogen 30 p. s.i., F.LD. air 28 p.s.i. 
The following columns were prepared and tested. 
i. 2m 6,5mm/0.D. glass column packed with A/W (acid wa shed) Dt4CS 
(dimethylchlorosilane) treated Chromosorb W coated with 2% S.E. 30. 
ii. 2m 3mm/ 0.D. stainless steel column packed with A/H DMCS treated 
Chromosorb W coated with 7.5% Ca r bowax 20M . 
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iii. 2m 3mrn/0.D . stainless steel col umn packed with A/\~ Df1C5 treated 
Chromo sorb W coated with 10% Apiezon L. 
iv . 2m 3mm/ 0.D. stainless steel column packed with A/Vi DMC5 treated 
Chromcsorb W coated with 15% Apiezon L. 
v. 2 x 2m 3mm/ 0.D. stainless steel columns packed with A/ Vi DMC5 treated 
Chromosorb W coated wi th 15% Api ezon L. 
vi. 2. x 4m 3mm/0.D. stainless steel columns packed with A/Vi DMC5 treated 
Chromosorb Vi coated with 2% 5.E . 30. 
vii. 2 x 4m 3mm/ 0.D. stainless steel columns packed with A/VI DMC5 treated 
Chromosorb W coated with 15% Api ezon L. 
i. A/W DMC5 treated Chromosorb W was suspended in a 2% solution of 5.E.30 
in toluene and degassed. This slurry was evaporated in a rotary evaporator 
and the packing heated in an oven at 100 °c for an hour to remove any 
remaining toluene. A 2m 6,5mm/ 0.D. glass column was washed three times 
-
with toluene, dried with compressed nitrogen and set up in a cushioned 
retort stand. A funnel was fitted to one end and the other was connected 
to a vacuum tap. Fine nylon gauze was used to prevent the support from 
being sucked through into the vacuum tap. Negative pressure was applied 
to the column and this, in conjunction with vibration from the rotary 
chuck of a drill, ensured even column packing . Glass wool was inserted 
into either end of the column to prevent the support escaping under 
carrier gas pressure. Front and back teflon ferrules were fitted to the 
column and one end was connected to the injection port inlet on the 
chromatograph. The column was conditioned overnight at 275 °c with a 
carrier flow rate of SOml/min. 
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Using authentic samples of SKF 525 A and SKF 8742 A, the oven temperature 
and carrier gas flow rate were varied in efforts to improve separation. 
Temperature programming was also used. 
Results and Discussion 
The following conditions were optimal for this column. 
Temp 1 Time 1 Rate Temp 2 Time 2 F.LD.Temp Inj.Temp Flow rate 
130 °c 6 min 30 °C/min 170 °c 15,0 min 120ml/min 
Time1 Rate Time 2 Cool 
TIME 
Temp 1 = initial oven temperature 
Time 1 = time at temp 1 
Rate = rate of increase in temperature 
Temp 2 = second oven temperature 
F.I.D.temp = flame ionization detector temperature 
Inj.temp = injection port temperature 
Flow rate = flow rate of carrier gas. 
The separation achieved with this column was not adequate and this may 
have been due to slight differences in materials to those used by Anders 
26 
et al. . Alternative systems were sought. 
ii. A/W DMCS treated Chromosorb W was coated with 7. 5% Carbowax 20 M. 
Chloroform was used as the solvent. Previously it was found that use of , 
the rotary evaporator did not lead to even coating; consequently the 
slurry was evaporated at 100 °c in an oven. Frequent stirring led to a 
homogenous product. In view of the fragility of the glass column a 2m , 
3mm/ 0.D. stainless steel column was u;ed. Due to its dimension and its 
non-transparency, this column was more difficult to pack . The volume of 
packing required was pre-determined wi th a fluid and it was necessary to 
vibrate the packing, in a measuring cylinder, down to this volume to obtain 
the amount required to closely pack the column . More vibration than 
before was required to bed down the support and care was taken not to 
further reduce the particle size of the diatomaceous earth . 
Results and Discus s ion 
The following conditions were optimal for this column. 
Temp 1 Time 1 Rate Temp 2 Time 2 F.I . D.temp Inj.Temp Flow rate 
230 °c 45ml/min 
This column was unsuitable as the retention times were excessive}y long and 
peaks were assymetrical . 
iii. A/W DMCS treated Chromosor b W was coated with 10% Apiezon L, packed 
into a 2m 3mm/ 0.D. stainless steel column and conditioned overnight at 
290 °C . 
Results and Discussion 
The following conditions were optimal for this column. 
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Temp 1 Time 1 Rate Temp 2 - Time 2 F.I;D;temp - -Inj.temp Flow rate 
90ml/min 
Separation using this column was not adequate and it was decided to increase 
the percentage of the liquid phase . This would increase the retention 
time but would also increase efficiency. 
iv. A/W DMCS treated Chromosorb W was coated with 15% Apiezon L, packed 
into a 2m 3mm/0.D. stainless steel column and conditioned overnight at 
290 °c 
Re sults and Discussion 
Optimal conditions for this column involved a temper~ture programme which 
reduced the retention time. 
Temp 1 Time 1 Rate Temp 2 Time 2 F. 1. D. temp Inj . temp Flow rate 
160 °c 3,0 min 25ml /min 
The temperature programme caused column bleeding and so a second identical 
column was prepared and the chromatograph was used in the dual column mode . 
Use of a temperature programme over a long term period was not ideal for, 
on continual removal and replacement of columns from the chromatograph, 
leaks developed which were difficult to eliminate. Isothermal conditions 
were investigated and the following conditions produced an adequate 
chromatogram (Fig. 7) . 
Temp 1 Time 1 Rate Temp 2 Time 2 F. I.D.temp Inj.temp Flow rate 
24ml/min 
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Fig 7 Chromatogram Of SKF 525-A And 
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While these columns appeared to meet requirements for analytical \York,it 
was necessary to further improve separation to enable g.l.c./mass 
spectrometry to be performed with the metabolites. Thus, further 
systems were investigated . 
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v. A/H D/·1CS treated Chromosorb G was coated with 15% Apiezon L, packed 
into 2 x 2m 3mm/0.D. stainless steel columns and conditioned overnight 
at 290 °C. 
Results and Discussion 
The following conditions were optimal. 
Temp 1 Time 1 Rate Temp 2 Time 2 F.I.D.temp Inj.temp Flow rate 
24ml/min 
These columns were not at all successful as the peaks were asymmetrical 
and had very long retention times. 
vi. A/\~ Dr~CS treated Chromosorb W coated with 2% S:E.30 was packed into 
2 x 4m 3mm/0.D. stainless steel columns and conditioned overnight. 
Results and Discussion 
The following conditions were optimal. 
Temp 1 Time 1 Rate Temp 2 Time 2 F.I.D.temp Inj.temp Flow rate 
20ml/min 
This resulted in good separation of the tertiary and secondary amines but 
the minor metabolite peak continued to overlap the secondary amine peak at 
high sensitivity. 
vi i. A/W DNCS treated Chromosorb W coated wi th 15% Api ezon L was packed 
into 2 x 4m 3mm/0. D. stainl ess steel col umns and conditioned overnight. 
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Results and Discussion 
Optimal conditions were as follows. 
Temp 1 Time 1 Rate Temp 2 Time 2 F;r.D.temp rnj.temp Flow rate 
2Om1/min 
Excellent separation of the tertiary and secondary amines was obtained but a 
contaminating product interfered with the minor metabolite peak. After 
investigation and purity checks of the authentic amine samples it appeared 
that the newly purchased support differed to that originally used and 
caused degradation of the secondary amine. 
(v) were used for future work. 
F.r . D. Sensitivity Test 
The co l umns as described in 
. As the production of the metabolites was expected to be sma11,a sensitivity 
test was performed to ensure their detection . 
Method and Results 
80 p1 of a 4 x 10-4 M solution of SKF 525 A was used for each ~etabo1ic 
incubation. A stock sol ution of 4 x 10-5 M SKF 525 A in methanol was 
prepared and ultimately 1 p1 of this was diluted 1:200. This dilute 
solution was injected into the chromatograph and appeared as a small peak 
on the chromatogram. 
Conclusion 
The F.r . D. is capable of detecting 1:160000 of each aliquot of SKF 525 A 
used in a metabolic incubation. Thus,the metabolites produced should be 
easily detectable. 
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Quantitative Gas Liquid Chromatography 
It was necessary to develop a quantitative g.l.c. procedure to analyse 
results from the metabolic studies envisaged. 
available were as follows 242 : 
The types of procedure 
1 . Area % This method does not require calibration.(To calibrate, 
a set volume containing known weights of different compounds is injected 
into the g.l.c. The integrator assigns percentage area to each peak,and 
the operator then enters into the computer the weight of each compound 
giving rise to its peak. In future runs,the computer will convert the 
area under each peak to the weight of compound presentJ It reports all 
peaks that meet with the slope sensitivity and area reject requirements 
but it does not correct for detector response. The simplicitY ,of this 
method allows accurate determination of the percentage composition,e.g. 
metabolic extracts. As the composition of the extracts does not change 
the detector response factor is insignificant for comparative purposes. 
2. Normalize Method This method requires calibration, it only reports 
the calibrated peaks and will correct for detector response . 
3. External Standard This method requires calibration and it only 
reports the calibrated peaks . It corrects for detector response but 
requires a highly reproducible injection procedure. 
introduction is a prerequisite. 
Automatic sample 
4. Internal Standard This method requires calibration; it only reports 
the calibrated peaks and corrects for detector response . This is accepted 
as being the most accurate quantitative method and requires a known amount 
of internal standard to be present in each sample. 
67 
The most suitable of the methods tested were the area % and the internal 
standard methods. The former procedure allows comparison of percentage · 
components in a mixture while the latter ~lill indicate the mass of each 
component. 
Area Per Cent Method 
Unless the Hewlett Packard integrator adheres to certain parameters it is 
not possible to obtain accurate results using any of these methods. The 
integrator is termed "software" and it is capable of reviewing stored 
data at . the end of each run. (A "hardware" integrator cannot review 
stored information and may only process it as it is received.) The integrator 
will automatically perform the following functions242 :- distinguish peaks 
from detector noise, determine the beginning and end of peaks, measure 
, 
retention times of peaks, correct for baseline drift, correct for 
asymmetric peaks, separate partially resolved peaks and tangent skim 
peaks on the tail of solvent peaks. Use of the area reject and slope 
sensitivity functions enables the integrator to reject peaks, ignore 
specific portions of the chromatogram, sum groups of ~djacent peaks, 
tangent skim designated peaks and analyse the detector signal and 
determine the maximum utilisable sensitivity. 
The slope sensitivity determines the gradient of the slope of the 
chromatogram at which the integrator will start recording the area of the 
peak. A slope sensitivity setting of 0,5 was generally found to be 
suitabl e. 
Use of the area reject facility in conjunction with a time programme 
enabled the integrator to ignore the large solvent peak which accounted 
for the majority of area . This led to more accurate designat"ion of 
percentage areas to the relevant peaks . 
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Internal Standard Method 
The area reject and slope sensitivity parameters as described, ~Iere also 
used for this method. An internal standard with the following properties 
was required. It should have a similar structure to the compounds being 
analysed, it should elute from the column in an area of the chromatogram 
not occupied by the sample peaks and it should be used in equivalent 
concentrations to the sample. This latter stipulation was difficult to 
meet due to the large variation in concentration between SKF 525 A and its 
metabo 1 i tes. 
Tests for an Internal Standard 
1. The following compounds were tested for suitability as an internal 
standard. They all produced suitable peaks but these, overl apped or 
interfered with SKF 525 A or its metabolites on the chromatogram. 
Temperature programming could not eliminate this problem. 
Compounds tested: imipramine, diphenhydramine, ephedrine, chlorpheniramine, 
mepyramine maleate, chloramine T, caffeine, scopolamine, scopolamine 
bromide, methyl nicotinate, dihydrolysergic acid. 
2. The following compounds did not produce a peak at all: 
Phenobarbitone, neostigmine bromide, brucine, gramine, guvacine, 
strophanthin, veratrine, l-dihydroxyphenylalanine, 4-methylaminophenolsulphate 
and acetylcholine. 
3. Hydrastine and berberine gave peaks that were not reproducible, 
testosterone tailed badly and theophylline would not have been suitable as 
it reacts with amines. 
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4. The most suitable compounds included: ethyl morphine, ethyl morphine 
Hel, and codeine phosphate . 
Codeine phosphate was finally chosen as internal standard but its 
dissimilarity in structure to SKF 525 A, its long retention time and slight 
tailing detracted from its value. See chromatogram, Fig. 8a. 
t1ethod 
The internal standard stock solution contained 0,12207g codeine phosphate/ 
100ml methanol . 
The internal standard calibration mixture contained 0,00650g SKF 525 A and 
0,00298g SKF 8742 A/7 , 5ml of internal standard stock solution. One ~ l of 
, 
this calibration solution was injected into the g.l.c. for calibration. 
After cal ibration each metabol ic extract was analysed with a specific 
volume of internal standard stock solution added. 
The calibration solution was packed into 2ml amber ampoules, sealed under 
nitrogen and kept in the refrigerator. The internal standard stock 
solution was packed in an amber bottle and was also refrigerated between 
runs . 
A very recent publication283 describes the use of SKF 525 A as an internal 
standard for the determination of trimethoprim in urine . Similar conditions 
were used and it appears that trimethoprim would be a more suitable internal 
standard to codeine phosphate. 
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Peak Shift Technique Studies 
A d d r' . 282,26 d 'b d th d h b d . t' n ers an 'Iannerlng escrl e a me 0 were y erlva lves were 
formed on the g.l.c, column by injecting volumes of acetone. acetic or 
propionic anhydrides. They used this method to facilitate identification 
of the metabolites of SKF 525 A. It is expected that anhydrides will form 
esters with phenolic and alcoholic hydroxyl groups on the column and 
amides with primary or secondary amines. 
amines to form Schiff base derivatives. 
Materials and t~ethods 
Acetone reacts with primary 
The following types and volumes of analytical grade derivative forming 
agents were injected into the column 5 seconds after the metabolic extract 
had been injected . 
Acetic and propionic anhydride 5 ~ l 
Acetone 5 ~l 
Results 
It was not possible to duplicate the results of Anders et ~,26 and while 
-
acetic and propionic anhydrides shifted the SKF 8742 A peak. at no stage 
did this reappear as a well defined peak with a reproducible retention 
tir.1e. 
Preparation of SKF 525 AN-oxide 
As the minor metabolite of SKF 525 A may possibly be an N-oxide;synthesis 
of SKF 525 A N-oxide as a reference material was undertaken284 and the 
reaction products were evaluated using g.l .c. 
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Material s and ~1ethods 
One 9 of SKF 525 A was dissolved in a minimum quantity of distilled 
water and the pH was adjusted to 7,8 with dilute NaOH. The resulting 
suspensi on was extracted with di ethyl ether and the extract was evaporated 
to leave the oily base. This was dissolved in 8ml analytical grade 
methanol and the solution incubated with 2,4ml 30% H202 at room temperature 
for three days. 
The oxidation mixture was stirred and cooled while 0,02g platinum oxide 
was added. The mixture was stirred for 3h, then filtered and the filtrate 
concentrated under vacuum to c.30% of its original volume. This 
concentrated solution was saturated with NaCl, giving rise to an oily 
layer, which was removed, dried and analysed by g.l.c. 
Results 
See chromatogram Fig. 8b. Oxidation of SKF 525 A gave rise to a number 
of different products, and the chromatogram indicated that both SKF 
8742 A and the minor metabolite had been produced. Without authentic 
N-oxide samples, it was difficult to identify peaks and attempts to 
purify the components of this mixture by column chromatography were 
unsuccessful. 
Due to the many contaminants, this approach, which apparently succeeded 
in the production of both metabolites of SKF 525 A, was not pursued. 
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. CHAPTER 4 
STUDIES ON THE r,lECHANISM OF HEPATICIUCROSor~AL SKF 525 A METABOLISM 
. Objectives 
The metabolism of nitrogen containing compounds, and particularly tertiary 
amines, had received increasing attention in recent years and attempts to 
isolate and characterise the enzyme system(s) responsible for the 
N-oxidation of tertiary amines have been made. Zeigler and co_workersl12 ,l13 
succeeded in purifying and characterising a mixed function amine oxidase 
which was devoid of cytochrome P-450 and NADPH-cytochrome c reductase 
and vlhich is responsible for the N-oxidation of some tertiary and secondary 
amines. 
Use of n-octylamine to stimulate 
well documented216 ,241,255,257. 
the microsomal amine ·oxidase system is 
Jefcoate et al. 86 have shown that this 
agent inhibits cytochrome P-450 mediated reactions and Prough and Zeigler255 
showed that the N-demethylation of four tertiary amines was inhibited from 
74 to 93% but that the 
partially inhibited. 
N-demethylation of secondary 
Poulsen et al. 257 found that 
amines was only 
~-octylamine eauses 
0-10% activation of demethylaniline N-oxidase in rat hepatic microsomes 
whereas it stimulates the same system by 146% in pork liver microsomes. 
Th~s, it was decided to use both these species in these studies. 
Evidence indicating participation of cytochrome P-450 in the N-oxidation of 
tertiary amines has been presented132 and recent studies254 ,255 confirm this 
participation. Hlavica and Keh1 254 have shown that cytochrome P-450 
accounts for 50-60% of the total N,N-dimethylaniline N-oxide formed in 
the rabbit liver microsomal fraction, the remainder arising from the 
action of the mixed function amine oxidase. Similarly, Prough and Zeigler255 
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have shown considerable participation by amine oxidase in the N-demethy1ation 
of benzphetamine and p-ch 1 oro-N-methy1 an i 1 ine, reacti ons previ ous 1y cons i dered 
to be cytochrome P-450 dependent . 
Thus, it appears that there is considerable overlap in the activity of these 
enzymes, and their influence on the metabolism of SKF 525 A, a widely used 
experimental tool, requires investigation. 
Materi a 1 sand 11ethods 
Microsomes and incubation mixtures were prepared as previously described 
(see chapter II). Microsomal preparations were obtained from · a) male, 
300-350g rats b) male swine and c) induced microsomes from female, 
200-250g rats injected i/p with 80mg/kg phenobarbital for three days 
before sacrifice. 
In all experiments,the microsomal protein concentration was adjusted to 
c. 5mg/m1 . 
Solutions of dithiothreito1 (10-3M and 10-2M) were added to the test 
-incubation mixtures before the addition of microsomes or isocitrate 
dehydrogenase . 
rqicrosomes were gassed with carbon monoxide for min and were protected 
from light (which may cause dissociation of the cytochrome P-450 CO 
comp1 ex). The CO gassed microsomes were added to the test incubation 
flasks (which were wrapped in aluminium foil to prevent penetration of 
1 ight.) before the addition of isocitrate dehydrogenase. The flasks 
were finally perfused with CO instead of oxygen and stoppered. 
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Three mM n-octylamine (1 ~l) was added to each test incubation flask after 
the addition of the distilled water and Mg++/Mn++ solution. 
were agitated to disperse the immiscible liquid . 
The flasks 
Studies with induced microsomes were performed li ke those using normal 
rat microsomes with the exception of the pretreatment of the rats with 
phenobarbital . 
Results 
Quantitative and qualitative differences in the metabolism of SKF 525 A 
and SKF 8742 A by induced rat · hepatic nlicrosomes are shown in the g. l . c. 
traces. See Figs. 9 and 10. 
SKF 525 A: - Induction causes a c . 100% increase in the production of 
SKF 8742 A but the formation of metabolite ·I appears to be littl~ 
affected. Induction does appear to cause the formation of another 
metabolite (termed metabolite IV) whose formation is inhibited by 
carbon monoxide . 
SKF 8742 A:- Induction greatly increases the formation of metabolite I 
and causes the formation of another metabolite (termed metabolite III) 
whose formation is inhibited by carbon monoxide . It is not possible to 
comment on the presence of metabolite IV under these conditions as the 
size of the metabolite I peak obscures its detection . 
The results (see Figs 11, 12, 13, 14 and 15) of duplicate experiments 
with rat hepatic microsomes are expressed as a percentage of the control 
(100%) value ~ standard deviation. Each experiment comprised four test 
·and four control incubations . Single experiments were performed with 
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Chromatograms Showing Metabolites Produced with Induced 
MicrOsomes 
R 9 Fig 10 
..... 
.ri 
o 
.-
OJ 
2 
77 
o 
L.. 
..... 
c: 
Fig 11 
150 
125 
100 
<3 75 
'0 
~ o 
50 
25 
o 
Metabolism of SKF 525-A Using Rat Hepatic Microsomes 
C 01 02 C CO C 0 
SKF 8742-A 
+ 
+ 
r 
C 01 02 . C CO C 0 
metabolite I 
~ 
Fig12 Metabolism of SKF 8742-A Using 
Rat Hepatic Microsomes 
125r (metabolite I) 
100~ or!- t- ~ 
751-
"0 
L.. 
+J 
C 
0 
u 
'050 
~ 0 
251- , , , , + .---
0' " " " , , , , " " C D1 D2 C CO C 0 
'-J 
l.O 
Fig13 Metabolism of SKF 525-A Using 
125 
Swine Hepatic Microsomes 
100 
75 
<5 
~ 
..... 
c 
0 
U 
-
50 0 
~ 0 
25 
• 
o r 
C 01 CO 0 C 01 CO 0 
SKF8742-A metabolite I 
125 
100 
75 
50 
25 
o 
Metabolism of SKF 8742-A Using 
Swine Hepatic Microsomes 
n r 
C 01 CO 0 
I metabolite I 
co 
o 
Fig14 Metabolism of SKF 525-A Using Induced Rat Hepatic Microsomes 
125 
100 
e 
-c o 
u 
75 
-50 o 
~ o 
2 
o C D1 CO 0 
SKF8742-A ! 
rt-
~ . F 
rt- f 
, 
C D1 CO 0 C D1 CO 0 
metabolite I metabolite IV 
co 
~ 
Fig 15 Metabolism of SKF 8742-A Using Induced 
Rat Hepatic Microsomes 
e 
..... 
c 
o 
u 
125 
100 
75 
-..- 50 
o 
~ o 
25 
o 
-
-
-
., 
, 
l-
T 
r+1 
C 01 CO 0 C 01 CO 0 
I metgboli te I metabolite ill 
OJ 
N 
swine hepatic microsomes and induced rat hepatic microsomes and the results 
were expressed as above. 
Key C contro 1 
Dl lmM dithiothreitol 
D2 lOmM dithiothreitol 
CO carbon monoxide 
0 3mM n-octyl amine. 
+ These values were too small to be measured with g.l.c. and the 
listed percentage control values are estimates. 
x The metabolites I and IV peaks merged and were thus expressed as 
one value. 
Discussion 
As induction of rats with phenobarbital will stimulate cytochrome P-450 
but not amine oxidase mediated reactions, microsomes prepared from 
induced rats serve as a useful tool to evaluate the enzyme systems 
involved in metabolism. 
The results of these studies performed with phenobarbital induced 
microsomes indicate that production of SKF 8742 A from SKF 525 A is 
mediated by cytochrome P-450. As metabolite IV is only present when 
induced microsomes are used, its formation probably is also catalysed 
by cytochrome P-450. Similarly, all metabolites of SKF 8742 A appear 
to be produced in cytochrome P-450 mediated reactions. 
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A problem arises however when consideration is given to the fact that 
metabolite I, derived from SKF 525 A, and metabolite I, derived from 
SKF 8742 A, are not produced in similar quantitative ratio when induced 
microsomes are used. Furthermore, it is apparent that metabolite III 
arises from conversion of SKF 8742 A by induced microsomes and, thus, 
the presence of this metabolite \~ould be expected in metabolic extracts 
derived from" SKF 525 A (due to formation of SKF 8742 A). Thi sis not 
the case . 
The inhibition studies strongly suggest that SKF 8742 A is produced from 
SKF 525 A by normal rat liver microsomes in a cytochrome P-450 mediated 
reaction. Dithiothreitol (lO-3M) failed to inhibit SKF 8742 A formation 
significantly, ~-octylamine failed to stimulate it and CD significantly 
inhibited the formation. Similarly, metabolite I also appeared to be 
formed in a cytochrome P-450 catalysed reaction. 
The production of metabolite I from SKF 8742 A also appears to be mediated 
by cytochrome P-450 and, while lO-3~1 dithiothreitol inhibits metabolite I 
formation by c .40%, only values as high as c .90% inhibition would be 
. d" t' f' 'd t" . t ' 251 ln lca lve 0 amlne OXl ase par lClpa lon . 
Use of swine liver microsomes failed to show amine oxidase involvement 
as ~-octylamine did not stimulate metabolite production. 
Inhibition studies involving phenobarbital induced microsomes did not 
indicate amine oxidase participation in the metabolism of SKF 525 A 
and SKF 8742 A. 
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CHAPTER 5 
PREPARATIVE TECHNIQUES 
Objectives 
Anders et al. 26 succeeded in separating the metabolites of SKF 525 A using 
thin layer chromatography but the minor metabolite was never identified. , 
It is therefore the aim of this work to separate the metabolites by 
non-destructive processes and to identify them. 
1. Thin Layer Chromatography (t.l.c.) 
~1aterials and Methods 
The following equipment was used . Gelman silicic acid and silica gel 
instant thin layer chromatography (I.T.L.C . ) plates, Gelman developing 
tank238 , Hewlett Packard 5830A g.l.c. All solvents used were of 
analytical ·grade. 
Spray Reagents 
i. Potassium iodoplatinate reagent for amines. 
Spray: 3ml of 10% platinum chloride and 97ml water + 100ml 6% potassium 
iodide. 
ii. Sodium nitroprusside reagent for secondary aliphatic and alicyclic 
ami nes. 
Spray: 5g sodium nitroprusside in 100ml of a 10% aqueous solution of 
aceta ldehyde. One volume of thi sis mi xed before use with 1 vol ume of 
1% sodium · carbonate. Primary amines react to produce a red colour and 
secondary amines produce a blue colour. 
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iii. Folin Ciocalteau reagent for phenols. 
iv. Diazotized p-nitro-aniline solution for phenols. 
Stock solution: dissolve 0,7g p-nitro-aniline in 9ml concentrated HCl 
and make up to 100ml with water. 
Spray: 4ml of stock solution added dropwise to 5ml of an ice-cooled 1% 
sodium carbonate solution and made up to 100ml ~Jith iced water. 
N.B. prepare freshly before use. 
A dual wavelength ultra-violet light source ·was also used to detect the 
presence of SKF 525 A and SKF 8742A. 
Pilot studies were run in microscope sl ide staining tanks using small 
strips of the I .T.L .C . plate . Solvent systems which produced promising 
results were re-tested in full scale in the Gelman tank after the 
atmosphere above the solvent had equilibrated for 10 minutes. On 
development, the strip was visualized under uv light and the spots marked. 
However, if the concentration of metabol ite was too small to show up 
under uv then the strip was cut in half longitudinally and one half was 
sprayed for amine to visualize separation of the major components. 
Unl ike the results of Anders et~. 26, the minor metabol ite did not show up 
as a blue spot on treatment with Folin reagent and this necessitated a 
g.l.c. check for separation. The unsprayed half of the plate was cut 
up transversely in regular sections, which were numbered . These were 
alkalinised with ammonia gas, extracted with diethylether and evaporated 
to dryness in a sample tube. The extracts were redissolved in methanol 
and analysed by g. l.c. 
Results 
A total of 89 solvent systems were used in an attempt to separate the 
metabolites of SKF 525 A. See Table 1. 
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TABLE 1 
I. T. L. C. OF SKF 525 A AND ~lETABOLITES 
No. S.A. S.G. Solvent System Results 
1 
2 
3 
* 
* 
4 * 
* 5 * 
6 
7 
8 
9 
10 
* 11 * 
12 * 
13 * 
14 * 
15 * 
16 * 
17 
18 * 
19 * 
20 * 
21 * 
* 22 * 
23 * 
24 
25 * 
* 
* 
* 
* 
* 
* 
* 
* 
No separation, tailing. EtOH:HAc:H20 (60:30:10) 
CHC1 3:MeOH (95:5) 
" (90:10) 
Slight separation,tailing. 
Slight separation,less tailing. 
Benzene: Acetone (50:50) 
CHC1 3:EtOH:NH3 (95,5 :4,5:0,5) 
CHC1 3 (100%) 
CHC1 3:EtOH (98:2) 
" (96:4) 
" (95:5) 
CHC1 3:DiethylaJ:1ine (99:1) 
" (98:2) 
" +EtOH (98:1:1) 
CHC1 3:Diethylamine (99:1) 
II +MeOH (97:2:1) 
CHC1 3:Diethylamine:acetone (94:1:5) 
" (97:1: 2) 
Benzene:Diethylamine 
" 
(98:2) 
(98:2) 
No separation, tailing. 
Good separation. 
No separation, tailing. 
No separation, tailing . 
No separation. 
,No separat i on. 
No separation. 
Some separation. 
No separation, tailing. 
No separation,less tailing. 
No separation,tailing. 
Better separ.ation, tail ing. 
Some separation. 
No separation. 
Some separation. 
" (96:4) Better separation. 
" (94:6) Separation, Rf too high. 
" (94:6 + 1 drop NH3) Ammonia immiscible. 
" (95:5) Good separation . 
CHC1 3:Diethylamine (99,9:0,1) No separation. 
Benzene: CHC1 3 
" 
(50:50) 
(50:50) 
Tailing. 
Tail ing. 
I 
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No. S.A. S.G. Sol vent System Resul ts 
26 * CHC1 3: EtOH: NH3 (93:4:3) Tailing. 
27 * " (90:6:4) Tailing. 
* 28 * CHC1 3: EtOH: Diethyl amine (96:1 :3) Good separation. 
29 * " (94:1:5) Slight separation. 
30 * Benzene: EtOH:Diethylamine (95:2:3) Slight separation. 
31 * " (94:3:3) Better separation. 
32 * " (92:5:3) Less separation. 
33 * " (90:5:5) Some separation. 
34 * . " (87:5:8) Some separation. 
35 * " (89:5:6) Some separation . 
36 * " (89:6:5) No separation. 
37 * " (88:7:5) No separation. 
, 
38 * Pet.Ether:Diethylamine (97:3) Separation, tailing. 
39 * " + EtOH (96:3:1) Separation, tailing. 
40 * Pet. Ether (100% ) No separation. 
41 * " + EtOH (98:2) No separation. 
42 * Pet.Ether:Diethylamine (94:6) Separation. 
* 43 * " (95:5) Good separation. 
. 
44 * Pet.Ether:HAc (98:2) No separation. 
45 * " (98:2) No separation. 
46 * " + EtOH (96:2:2) No separation. 
47 * " (96:2:2) No separation. 
48 * CHC1 3: HAc (98:2) Tailing. 
49 * " (98:2) Tail ing. 
50 * " + EtOH (96:2:2) No separation. 
51 * " (98,5:1 :0,5) Tail ing. 
52 * " (98,5:1 :0,5) Tailing. 
53 * CHC1 3:HAc:acetone (98: 1 : 1 ) Tailing. 
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No. S.A. S. G. Solvent System Results 
54 * CHC1 3:HAc:acetone (98:1:1) Tailing. 
55 * Benzene:EtOH + 1 d HCl di 1. (98:2) HCl immiscible. 
56 * " (98:2) HCl immiscible. 
57 * Benzene:HAc:EtOH (97:1:2) No separation. 
58 * " (97 :1 :2) No separation. 
59 * " (96:1 :3) No separation. 
60 * " (96:1 :3) No separation. 
61 * Benzene: HAc: Dioxane (97: 1 : 2) No separation . 
62 * " (97:1 :2) Tail ing. 
63 * . " (95:1:4) No separation. 
64 * " (95:1:4) Tailing. 
65 * " (93:1 :6) No separation. 
66 * " (91 :3:6) No separation. 
67 * " (91:3:6) Tailing . 
68 * To 1 uene: HAc: EtOH (97: 1 :2) No separation. 
69 * " (97:1 :2) Tailing . 
70 * Pet.Ether:HAc:EtOH (94:2:4) No separation. 
71 * " (94:2:4) Tailing. 
72 * " (92:2:6) Tail ing. 
73 * Pet.Ether:CHC1 3:HAc:EtOH (70:25:2:3) Tail ing. 
74 * Et Ac:Benzene:HAc (70:28:2) No separation. 
75 * " (70:28:2) Tailing . 
76x * Pet.Ether (100%) No separation. 
nX 
* " (100% ) Tailing. 
78x * Pet.Ether:Diethylamine (95:5) Some separation. 
79x * " (95:5) No separation. 
80x * " (99:1) No separation. 
81 x * " (99.1 ) No separation. 
No. S.A. S.G. Solvent System Results 
82*x * Pet-Ether:EtOH (98:2) Separation. 
83x * " (98: 2) No separation. 
84x * Hexane:EtOH (98: 2) No separation. 
85x * " (98:2) No separation. 
86x * Toluene:EtOH (98:2) Separation. 
87x * " (98:2) No separation. 
88x * Benzene:acetone:EtOH (89:9:2) Some separation. 
89x * " t89: 9:2) No separation. 
S. A. Sil icic acid plate 
S.G. Silica gel plate 
* 5 Full size plate run, cut into strips and analysed by g.l.c. 
76x Plates saturated with 0,95% NaOH spray before spotting 
EtOH 95% Ethanol 
HAc Glacial acetic acid 
Pet. Ether - petroleum ether 
CHC1 3 chloroform 
MeOH methanol 
Et Ac ethyl acetate. 
ld one drop 
5* In spite of the good separation apparently obtained using the I.T.L.C. 
method with this solvent,the g.l.c. strip analysis of the plate showed 
considerable contamination of the SKF 525 A and SKF 8742 A spots with one 
another. 
11* This solvent system produced a chromatogram in which the minor 
metabolite was still contaminated with SKF 8742 A but it trailed behind the 
secondary amine to a large degree. 
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* 22 This solvent system was used to separate a mixture of pure SKF 525 A 
and SKF 8742 A. These two spots had an Rf value of 0,87 and 0,79 
respectively . When metabolic extracts were run on the plate and analysed 
by g.l.c. there was considerable contamination of each component and the 
minor metabolite did not separate at all from SKF 8742 A. 
* * 28 This solvent system gave much the same result as solvent 11 where 
the minor metabolite lagged behind SKF 8742 A. Thus, it appeared that 
metabolite I was less polar than SKF 8742A. The polarity of the solvent 
system was varied with ethanol in solvents 30-37 but this had no separative 
effect. 
* 43 This solvent system produced excellent separation of the tertiary 
and secondary amine but did not separate the minor metabolite from SKF 
8742 A. As neutral or basic solvents had been used up to this stage, it 
was decided to test the effects of acidic systems . These were not at all 
successful. 
* 82 Plates sprayed with sodium hydroxide as described were spotted and 
run in this solvent system. SKF 525 A and SKF 8742 A were apparently well 
separated with Rf values of 0,98 and 0,60 respectively. When the thin 
layer chromatogram was examined by g.l.c. strip analysis contamination was , 
evident. 
In view of the excellent separation obtained on the I.T.L.C. plates but 
the lack of purity of the amine spots it was felt that other techniques 
should be investigated in an attempt to separate the metabolites as a sample 
with a high degree of purity was required. 
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2. Paper Chromatography 
Materials and Methods 
Medium flow rate lvhatman chromatography paper was used in preference to 
fast flow rate paper as the former was likely to afford better separation. 
Paper chromatography was conducted in the same manner as the I .T.L.C. and 
analytical grade solvents were used . 
Results 
TABLE II 
So 1 vent Sys terns Resul t 
CHC1 3 :MeOH (90:10) Tailed. 
2 MeOH (100% ) Tailed . 
3 Pet. Ether (100%) No separation. 
4 MeOH:NH3 (SO:20) Tailed. 
5 MeOH:HAc (SO:20) Tail ed. 
6 Pet.Ether:NH3 (97:3) No separation. 
7 Pet.Ether:Diethy1amine (97:3) No separation. 
S Dioxane:H20:NH3 (90:S:2) Ta i led. 
9 Acetone:NH3 (90:10) Tailed. 
10 EtOH:NH3 (9S:2) Tailed . 
_This technique did not look at all promising and was thus abandoned. 
3. Column Chromatography 
Materials and Methods 
The following equipment was used in these studies. Glass chromatography 
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co1umns,an L.K.B . 7000 U1trarac fraction collector and the Hewlett Packard 
5830 A g.l .c. 
A glass column, aOcm long and 1,5cm in diameter, was constructed with a 
No. 1 sinter fused into one end . Proximal to this, leaving the minimum 
of dead space, a teflon tap was affixed. At the other end of the column a 
Quick-fit joint was fitted . The purpose of the sinter was to prevent 
gel leakage from the column . Previously glass wool had been used for 
this purpose but was unsuitable. The dead space after the sinter was 
kept as small as possible to prevent mixing and tailing of the separated 
components. The inlet t6 the column was constructed with a Quick-fit 
glass stopper through which a thin glass tube passed. The outer end of 
, 
the tube was drawn fine and teflon tubing (lmm 1.0 . ) was attached to this. 
Similarly teflon tubing was attached to the bottom end of the column 
leading to the fraction collector. 
Sephadex L. H. 20 was allowed to swell for 90 minutes in a mi xture of 
ch10roform:methano1 (1:1). At the end of this period, 2 volumes of 
hexane were added and the gel was degassed under vacuum for 3 minutes. 
After the column had been washed, the slurry was gently passed into the 
column to avoid the incorporation .of air bubbles. So 1 vent was run 
through the column for 24h to allow it to settle and stabilize then a 
solution of Sudan III was passed through to check for aeration. A 
circular disc of filter paper was cut to the correct size and placed on 
top of the gel bed to prevent foreign particles from entering the gel. 
Sample application was done in one of two ways. 1. The sample 
was dissolved in chloroform and, with the use of a pasteur pipette, 
was allowed to form a denser layer above the gel. 2. The solvent 
layer above the gel was removed and as the filter paper was exposed, so 
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the sample, dissolved in a minimal volume of solvent, was applied. As this 
ran dry it was "washed" into the gel by successive appl ications of small 
volumes of solvent. The latter method was preferred as the former 
involved the use of a different solvent to that used for elution and 
further, while the dense chloroform layer apparently remained intact 
diffusion of the sample could have occurred to cause tailing. 
O1ce the sample :had been successfully applied, the elution solvent was 
siphoned into the top of the column and by removing air bubbles a continuous 
flow system was established. Flow rate was set by altering the height 
of the solvent reservoir. Fractions were collected using an L.K.B . 
7000 Ultrarac fraction collector. Each fraction was evaporated to dryness, 
diluted to a specific volume with methanol and analysed using g.l.c. 
All solvents used were analytical reagent grade. 
Results 
1. When chloroform:methanol:hexane (1:1 :2) was used, the separation achieved 
between the two components in a mixture of SKF 525 A and SKF 8742 A is 
shown on the following graph (see Fig. 16). 
Flow rate = 4 drops/min (c. 46 drops = lml). 
2. Metabolites were prepared and a sample was applied to the column. 
The same conditions as in 1 were used. 
separated from SKF 8742 A. 
The minor metabolite was not 
3. A new solvent system comprising methanol:hexane:chloroform (4:2:1) 
was used after the column had been conditioned for 24h. 
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Fig16 Seperation Between SKF 525-A & SKF 8742-A Using Sephadex LH 20 
16 • SKF 525-A 
-0- SKF 8742-A 
12 
<t:8 
4 
15 Fraction No. 20 
Area %. is a measure of the g. l.c . detector response. 
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Flow rate 4 drops/min. 
SKF 8742 A. 
The minor metabolite was not separated from 
4. The solvent system comprising chloroform:hexane:methanol (4:2:1) was 
used after the column had been conditioned for 24h . 
Flow rate 4 drops/min. 
SKF 8742 A. 
The minor metabolite was not separated from 
5. Solvent system 1 appeared to afford the best separation and so this 
was reused with a slower flow rate. 
Flow rate 2 drops/min. This did not noti ceably improve separation. 
It was decided to increase column length to 2 m. A 2m, co il ed, 
6mmlO.D., glass, g.l.c. column was converted for this purpose by 
embedding a sinter at one end and introducing a Y tube at the other. 
On one arm of the Y tube was fitted a Quick-fit joint and stopper while 
the other was drawn out to accommodate the teflon tube . Dead space 
below the sinter was kept to a minimum and a tap was not fitted . - This 
column was difficult to pack due to its length and small diameter and 
negative and positive pressure had to be used appropriately. The 
column was fitted to just below the level of the Y tube and the sample 
was introduced via the Quick- fit joint . The sample was encouraged to 
enter the gel by applying positive pressure. The column was conditioned 
for 24h and the following solvent systems were used. 
1. Chloroform:methanol:hexane (1 :1:2) 
Flow rate 1 drop every 90s. 
No separation . 
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2. Methano1:hexane :ch1oroform (4:2:1) 
Flow rate 1 drop every 90s. 
No separation. 
3. Ch1oroform:hexane:methano1 (4 :2:1) 
Flow rate 1 drop every 90s. 
No separation. 
4. Pyri dine: methano 1 : hexane (3: 1 : 1 ) 
Flow rate 1 drop every 90s . 
No separation. 
This technique was abandoned as it was time consuming and did not loo k 
promising . 
G.1.c./mass spectrometry will have to be relied on to elucidate the 
structure of the minor metabolite . 
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CONCLUSION 
The pH optima for CO and for drug binding to cytochrome P-450, not 
unexpectedly, differ from one another. Different binding sites on the 
enzyme are involved and it is quite possible that, at different pHs the 
conformation of the protein changes, thus hindering or facilitating access 
of the agent to its binding site. 
The observed difference in pH optima for the formation of SKF 8742 A and 
metabol ·ite 1 is more difficult to explain . Gorrod132 has pointed out 
that pH dependent metabolic studies may yield inconclusive results since 
the stability of the products will affect the quantity of metabolites 
formed. Metabolite I may be more stable at lower pH values and this 
increased stability would explain its higher incidence at pH 7,5. The 
results obtained in this study point to the involvement of cytochrome P-450 
since the pH optimum for the amine oxidase system is c . 8,6215 . 
The stabil Hy tests performed on the metabol ites indicate that they are 
stable to further oxidation at room temperature. These tests were 
performed using g.l.c. analysis and consideration must be given to the 
high temperatures involved in this process as U is unlikely that a room 
temperature dependent change will be effectively monitored with g.l.c . 
Possibly the ideal method for studying these metabol ites woul d be high , 
pressure liquid chromatography. In fact, pilot studies were performed 
with a Varian 8500 but teething troubles after its recent installation 
and the expense of purchasing the ideal column precluded pursuit in this 
area. 
98 
The physical properties of the metabolites of SKF 525 A appear to be similar 
in that a) both the secondary amine and metabolite I were efficiently 
extracted by the process used and bl extensive investigation of techniques 
for separation were all unsuccessful. These similarities in behaviour 
make unlikely the possibility that metabolite I may be a polar N-oxide . 
The search for a suitable internal standard for g.l .c. may have an added 
value as many of the compounds tested were well resolved by the columns 
used and, with little further effort, could quite possibly be analysed 
by the methods outlined for other studies. 
Contrary to the findings of Anders et ~.26, this study has shown SKF 
8742 A to be metabolised to a compound with an identical g.l .c. retention 
time to that of metabol ite I derived from SKF 525 A. ' In fact, this 
metabolite of the secondary amine has been referred to in this work as 
metabo 1 i te 1. However, these tI~o compounds cannot be fully accepted 
as being identical until further studies have been performed on them. 
Unfortunately, information from samples submitted to another institution 
for g.l . c./mass spectrographic analysis has not been forthcoming . 
A further query as to the identical nature of metabol ites I is raised 11hen 
biotransformation of these compounds is undertaken with phenobarbital 
induced microsomes. ' Netabol ism of SKF 8742 A is then enhanced whereas , 
production of metabolite I from SKF 525 A remains unchanged. 
As metabolite I is the main metabolite of SKF 8742 A it may be expected to , 
increase when induced microsomes are used, more than the expected 
production of a secondary metabolite which would be the case if SKF 
525 A was converted to SKF 8742 A, from which metabolite I was formed; 
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The pattern of metabolites from the two compounds differ quantitatively 
' and qualitatively on induction and this may be indicative of some change 
taking place in the mixed function oxidase system. 
Zeigler and Pettitl07 have suggested that two somewhat different enzyme 
systems may be active in the metabolism of some dru9s and this situation 
may apply to SKF 525 A. 
The results of the inhibitor studies favour the involvement of cytochrome 
P-450 alone but the failure to increase production of metabolite I from 
- , 
SKF 525 A with induced microsomes raises some doubt about this 
concl usion. 
Viewing the problem of enzyme involvement from a theoretical standpoint, 
one expects that the size of the molecule220 , its basicity132 and the fact 
that it is a tertiary amine l03 ,105 would favour the involvement of the 
amine oxidase system. However it has been shown that diethyl substitution , 
on the nitrogen of at least some compounds gives rise to derivatives 
which cannot be converted to an N-oxide. Furthermore it is well , 
established that SKF 525 A is N-dealkylated to produce SKF 8742 ~ in what 
may be the first stage in the biotransformation. It is not possible to 
say whether metabolite I is produced directly from SKF 525 A or SKF 
8742 A or whether it is a stable intermediate involved in the conversion 
of the former to the latter molecule. Carefully conducted kinetic 
studies -on the metabolism of these compounds should cast more light on 
this matter. 
Activities of the mixed function oxidase and of the amine oxidase systems 
have been shown to overlap but uncertainty over which enzyme may be , 
involved in a particular metabolic step does not prevent speculation as 
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to the structure of the metabol ites. In fact, the same products may 
aris e via different pathways254. The following possibilities may occur 
as the result of metabolism of SKF 525 A. See Fig. 17. 
i) Conversion of SKF 525 A to an a-carbinol amine intermediate, which, 
if stable, may comprise metabolite I. Dealkylation would follow to 
form the secondary amine. 
ii) If an N-oxide is implicated, then the following pathway is likely: 
SKF 525 A would be converted to the N-oxide, which would form the 
a-carbinol amine and this would dealkylate to form SKF 8742 A. 
iii) SKF 8742 A may be converted to the hydroxylamine derivative. 
These possibilities lead to the suggestion that the unidentified minor 
metabolite of SKF 525 A may be either a stable a-carbinol amine intermediate 
or the hydroxylamine derivative. It is felt that the latter product is a 
more likely candidate as SKF 8742 A has been shown to be susceptible to 
further metabolic conversion. 
This study is incomplete,and apart from g.l.c./mass spectrographic 
analysis of metabolites, a number of avenues are open for further 
investigation. 
Methimazole may possibly be the most specific amine oxidase inhibitor used 
to date255 . It may prove to be more satisfactory than dithiothreitol in 
implicating this oxidase for, as Mull ~~.204 have found, cysteamine 
(a compound with a similar function to dithiothreitol) has been shown to 
inhibit cytochrome P-450 mediated reactions as well. This fact may 
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Possible Metabolic Pathways For SKF 525-A 
. Fig17 
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explain some of the inhibitory effects of dithiothreitol in this study , 
effects which were greater than might otherwise have been expected fo r a 
cytochrome P-450 dependent reaction. 
Pretreatment of animals with COC1 2
285 has been shown to reduce levels of 
cytochrome P-450,and a study with this compound may prove useful in 
further evaluating enzyme pathways involved. 
Treatment of microsomes with detergents may also be a useful tool as this 
procedure decreases cytochrome P-450 activity but has little effect on 
the amine oxidase systeml07 . 
No induction study is really complete until the effects of both 
phenobarbital and the polycyclic hydrocarbons have been evaluated since 
induction with benzpyrene is known to alter metabolite patterns in many 
cases. 
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